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ABSTRACT 
Long-term antiviral antibody responses provide protection from re-infection and 
recurrence of persistent viruses. Using a polyomavirus (PyV) mouse model, our 
lab has shown that MyD88-deficient mice generate low levels of virus-specific 
IgG after the acute phase of infection and that these IgG responses have a 
skewed isotype distribution with low levels of IgG2a/c. MoreoverMyD88-
deficientmice have reduced numbers of long-lived plasma cells in the bone 
marrow. These studies suggest an important role of MyD88-mediated signaling in 
long-term antiviral responses. Our lab has shown that T cell-deficient mice can 
also maintain long-term virus-specific IgG responses following PyV infection. The 
goal of this thesis is to evaluate the role of innate signaling pathways in 
maintaining serological memory to persistent virus infection and to elaborate on 
how long-term antiviral responses can be maintained in an immunocompetent or 
partially immune compromised, T cell-deficient host.  
 Regarding T cell-dependent B cell responses, I set out to investigate the 
upstream and downstream components of the MyD88-mediated pathways 
required for normal antibody isotype and long-term humoral responses. 
IgG2a is a predominant immunoglobulin isotype in most virus infections. 
Wild type mice, in response to PyV infection, primarily induce antiviral IgG2a with 
some IgG1. MyD88-deficient mice in response to PyV infection display 
attenuated levels of virus-specific IgG2a, but normal levels of IgG1. Using 
Unc93B1 mutant mice (3d mice), which are defective in TLRs 3, 7 and 9 
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signaling, I show that 3d mice also generated low levels of virus-specific IgG2a 
following PyV infection. Studies in individual TLR3-/-, TLR7-/- or TLR9-/- mice 
displayed PyV-specific IgG2a responses similar to wild type responses. TLR7 
and TLR9 double deficient mice generated similar skewed antibody isotype 
responses, where virus-specific IgG2a was reduced compared to wild type mice. 
This shows that TLR7 and TLR9-MyD88 mediated pathways are important in 
regulating IgG2a responses during a PyV infection. 
To investigate what components downstream of MyD88 are involved in 
mediating IgG2a responses, I worked with IRF5-deficient mice. IRF5 is a 
transcription factor that is activated upon stimulation of TLR7 or TLR9-MyD88- 
mediated pathways. Moreover, IRF5-deficient mice cannot generate 
autoantibodies specifically of the IgG2a isotype in a mouse lupus model, 
suggesting that IRF5 plays an important function in mediating class switching to 
IgG2a. In vitro studies where IRF5-/- B cells were stimulated with TLR7 or TLR9 
ligands also generated low levels of γ2a germ-line transcripts, suggesting a B 
cell-intrinsic role for IRF5 in regulating γ2a germ-line transcription. PyV infection 
of IRF5-deficient mice resulted in similar skewed isotypes as observed in MyD88-
deficient and 3d mice. To investigate a B cell-intrinsic role for IRF5 in regulating 
IgG2a responses in vivo upon PyV infection, I transferred IRF5-/- B cells and WT 
T cells into RAG KO mice prior to infection and compared the responses of these 
mice with mice reconstituted with wild type B6 B and T cells. Diminished 
numbers of IgG2a+ B cells and reduced levels of virus-specific IgG in mice 
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reconstituted with IRF5-/- B cells were seen compared to mice reconstituted with 
wild type B cells.  
 Regarding the defect in long-term IgG production in MyD88-/- mice upon 
PyV infection, I conducted studies in IRF5-/-, 3d, single TLR3-/-, TLR7-/-, TLR9-/- 
and TLR7/9 double deficient mice. These studies reveal an important and 
redundant role for TLR7- and TLR9-MyD88 signaling in maintaining long-term 
anti-PyV IgG responses. To determine how MyD88 signaling affects the 
generation of long-lived plasma cells and memory B cells, I investigated germinal 
center  (GC) responses in MyD88-deficient mice. A defect in GC B cell numbers 
is observed in MyD88-deficient mice after the acute phase of infection. The GC 
reaction is essential for the generation and maintenance of long-lived plasma 
cells and memory B cells. T follicular helper (TFH) cells are absolutely required to 
generate normal GC. l found reduced numbers of TFH cells in MyD88-deficient 
mice. Lower numbers of T FH cells suggests that poor T cell help may contribute 
to the diminished number of GC B cells. However, interaction with B cells is 
required for the formation of fully differentiated TFH cells. Along with B cell 
function, MyD88 signaling can affect T cell and dendritic cell function as well. 
Thus, it is not clear at this point whether the requirement for intact MyD88 
signaling for the formation and maintenance of long-term B cell populations is 
completely B cell-intrinsic.  
Some viruses can induce T cell-independent B cell responses, perhaps 
due to their complex arrays of repetitive antigenic epitopes on virions, coupled 
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with the induction of innate cytokines. Nevertheless, T cell help is usually 
necessary for generating long-term antibody responses in the form of long-lived 
plasma cells and memory B cells. In contrast, our lab has found that T cell-
deficient mice infected with PyV develop long-lasting, protective antiviral IgG 
responses. I questioned whether these mice could generate TI B cell memory 
cells or long-lived plasma cells. I show that long-lasting anti-PyV antibody in T 
cell-deficient mice was not due to the presence of long-lived plasma cells or 
memory B cell responses.  
TCRβδ deficient mice, which lack both CD4 and CD8 T cells, had ~10 a 
times higher virus load persisting in various organs. Therefore, I hypothesized 
that the high level of persistent PyV antigen, in completely T cell-deficient mice, 
may activate naïve B cell populations continuously, thereby maintaining the long-
lasting IgG responses. Prior to PyV infection, T cell-deficient received wild type 
CD8 T cells, which reduced PyV loads, and this was associated with decreased 
levels of antiviral serum IgG over time. As in TCRβδ deficient mice, high PyV 
loads were detected in the bone marrow, which is the site for B cell 
lymphopoiesis, I questioned how B cells develop in the presence of PyV antigen 
and still stay responsive to PyV, generating long-term antiviral IgG responses in 
the periphery. Studies have shown that self-antigens that trigger both B cell 
receptor signaling and TLR-MyD88 signaling pathways in the bone marrow lead 
to the breaking of B cell tolerance and production of autoantibody in the 
periphery. Thus, we hypothesized that high PyV levels in the bone marrow signal 
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through both B cell-receptors and TLRs, allowing continuous antiviral antibody 
production by B cells. Using mice that are deficient in T cells and MyD88 
signaling, I found that PyV-specific TI IgG levels gradually decreased, supporting 
this hypothesis. Thus, high PyV loads and innate signaling together can break B 
cell tolerance. During a persistent virus infection this can result in sustaining 
long-term protective T cell-independent IgG responses. 
x
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CHAPTER I: Introduction 
 
A. Rationale and outline for thesis 
This thesis will examine the role(s) of innate signaling pathways in the 
maintenance of long-term antibody responses during a persistent virus infection 
in the presence and in the absence of T cell help. Antibody responses play 
multiple roles in virus infection. During the acute phase of infection, efficient 
antibody production can aid in viral clearance. Additionally, the long-term 
antibody responses generated during an acute infection by the formation of long-
lived plasma cells (PC) and memory B (Bmem) cells help to prevent re-infection 
with the same virus as well as the recrudescence or reactivation of persistent 
infections, and the development of disease. I wanted to investigate how long-
lasting antibody responses are generated and maintained during a persistent 
viral infection to achieve low-level viral persistence resulting from the delicate 
balance between antiviral host mechanisms and virus replication.  
To accomplish this goal, I utilized a mouse model of polyomavirus (PyV) 
infection, in which both T cell-dependent (TD) and T cell-independent (TI) B cell 
responses to viral antigens are generated (1). PyV infection of wild type (WT) 
mice results in low-level, life-long viral persistence with no associated disease. In 
immune compromised mice, such as mice lacking T cells, PyV persists at higher 
viral loads. These high viral loads in the absence of appropriate anti-tumor 
responses can result in tumor formation (2). Thus, normal immune responses are 
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required for a disease-free, life-long persistence of PyV infection in mice. My 
studies expanded on a previous finding of our laboratory that showed mice 
deficient in myeloid differentiation primary response gene 88 (MyD88) have 
defects in long-term humoral immunity in response to PyV infection (3). MyD88 is 
a vital adaptor linking certain cytokine receptors (e.g. IL-1R/ IL-18R) and toll-like 
receptors (TLRs) to intracellular signaling pathways. These results strongly 
suggest that innate receptors are required for sustaining antibody responses. My 
studies will demonstrate that MyD88-deficient (MyD88-/-) mice have defective 
memory B cell responses and, as previously established, lack long-lived bone 
marrow (BM) plasma cells and have skewed immunoglobulin G (IgG) isotypes. I 
want to determine the molecules upstream and downstream of MyD88 required 
in preserving long-term antiviral TD B cell responses. Investigating the role of 
MyD88-mediated pathways, I show that TLR7/TLR9- MyD88-IRF5 pathways are 
important for antiviral IgG2a/c isotype production and that these pathways are 
likely to play an essential role in the generation of long-lived IgG responses to 
virus infection. By addressing the MyD88-mediated mechanisms involved in long-
term humoral immunity, I show that a defect in MyD88 is associated with poor 
maintenance of germinal center (GC) responses. Thus, both innate receptors 
(TLRs) and helper CD4 T cells play an important role in maintaining long-lasting 
antiviral antibody responses to a persistent viral infection. 
T cell-deficient (TCR (T cell receptor) βδ KO) mice can generate long-
lasting virus-specific IgG (Immunoglobulin G) responses following PyV infection, 
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suggesting that PyV can induce TI B cell memory-like response (1, 4). Generally, 
TI B cell responses are thought to generate short-term antibody responses. 
However, other models have suggested that certain TI antigens such as 4-
hydroxy-(3-nitrophenyl)-acetyl-Ficoll (NP-Ficoll) can elicit a memory B cell 
response defined as quiescent, nonsecretory, and isotype switched cells (5). B 
cell proliferation to NP-Ficoll-secondary challenge was tested, but not recall 
antibody responses (5). 
 Using a novel memory B cell assay, I will demonstrate that long-term 
PyV-specific IgG responses in TCRβδ KO mice are not due to TI recall memory 
IgG responses but are instead due to continuous activation of nascent B cells 
emerging from the bone marrow into an environment of persistent virus infection. 
I will also show that innate MyD88-mediated signaling and persistent high viral 
loads are essential for maintaining long-lasting TI IgG responses in the PyV 
model. 
This thesis will describe how innate receptors directly and indirectly 
influence the preservation of long-lasting IgG responses to PyV infection in mice. 
Furthermore, this thesis will provide an insight into the generation and 
maintenance of long-term B cell responses that may also be applied to other 
persistent virus infections. 
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B. Humoral Immunity: TD versus TI B cell responses 
Depending on the type of antigen, B cells can generate TD or TI B cell 
responses. TD B cell responses generated by protein antigens result in GC 
formation and the development of memory and long-lived B cell responses. 
During a viral infection, a B cell requires two signals to be fully activated. The 
viral antigen cross-linking the BCR (B cell receptor) provides the first signal, while 
the second signal is from helper T cells. With the help from specialized CD4 T 
cells known as T follicular helper cells (TFH), GC are formed, where B cells go 
through massive rounds of proliferation, somatic hypermutation (SHM), class 
switch recombination (CSR) and a selection process that results in affinity-
matured, antigen-specific long-lived B cell populations. (Figure 1.1) 
TI antibody responses are divided into two basic categories: TI-type I (TI-
1) or TI-type II (TI-2) antibody responses. TI antibody responses are generated 
outside the follicle in response to various TI antigens. TI-1 antibody responses 
are generated by B cell mitogens (e.g. lipopolysaccharide (LPS)) that cause 
polyclonal B cell proliferation. Antigens with repetitive structures such as bacterial 
polysaccharides generate TI-2 antibody responses (6). TI-2 antigens strongly 
activate the B cell receptor (BCR) and T cell help is not required. TI-2 antigens 
are identified by their inability to induce an antibody response from BTK deficient 
(Xid mice) B cells (7). BTK is important in B cell maturation and for signaling  
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Figure 1.1- General schematic of TD and TI B cell responses  
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Figure 1.1: B cells generate antibody either in the presence (upper part) or 
absence (bottom part) of T cell-help. Long-term T cell-dependent antibody 
responses require the formation of GC responses, while T cell-independent 
antibody responses are generally thought to be short-lived. 
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downstream of the B cell receptor. In a TI B cell response, activation of B cells 
requires interaction of BCR and/or TLRs with antigen, along with help from 
cytokines. TI B cell responses are generally thought to be extrafollicular, short-
lived and devoid of GC. (Figure 1.1) Under certain conditions such as 
immunization with high doses of TI antigen (NP-Ficoll), GC can form (8). 
However, these TI GC are rapidly induced, have a short duration, and do not 
support SHM in the absence of T cell help (9). 
 
C. B cell subsets  
B1 and B2 B cell subsets are important in generating TI and TD B cell responses.  
B1 cells are divided into two types of B cells: B1a and B1b cells. B1b cells 
generate a TI B cell response and develop in the fetal liver. B1a and B1b cells 
are self-renewing and are generally found in the peritoneal cavity (6, 10). B1b 
and B1a cells represent an innate response by B cells and these cells produce 
natural antibody (11). The surface expression of CD5 distinguishes B1b (CD5-) 
and B1a (CD5+) cells (6, 10). 
 B2 B cells include marginal zone (MZ) B cells and the follicular B cells. MZ 
B cells are found surrounding the lymphoid follicle in the spleen and lymph 
nodes. MZ B cells, in the spleen, sense blood-borne antigens and provide a first 
line of B cell defense against antigens. MZ B cells generate a rapid, early, TI B 
cell response. MZ B cells are different from B2 B cells by expressing lower levels 
of CD23, a low affinity Fc epsilon receptor, and high levels of CD21, a 
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complement receptor. (11-13) B1a, B1b and MZ B cells have an important role in 
TI B cell responses. (6) 
 Follicular B cells are found within the B cell follicles in secondary lymphoid 
organs. The activation of follicular B cells is usually dependent on T cell help. 
Follicular B cells are phenotypically described as cells with high levels of CD21 
and CD23. Activation of follicular B cells leads to GC responses, which are 
crucial for the formation of long-lived B cell populations. (11) 
 
D. Antibody function and antiviral B cell responses 
B cells that function in a TD or TI manner have multiple effector functions. They 
secrete antibodies, secrete soluble immunomodulatory factors (cytokines) and 
affect the activity of other cells via surface molecules. B cells are APCs that can 
activate T cells by their major histocompatibility complex (MHC) and processed 
peptide complexes. Antibodies are the secreted form of the BCR. 
Immunoglobulin (antibody) is, for the most part, a homodimeric protein that 
contains 2 heavy chains and 2 lights chains that are connected by disulfide 
bonds. Antibody can also be described by the antigen-binding region (Fab or 
variable region) and by their Fc (or constant) region.  
Secreted antibodies can circulate throughout the body and provide protection 
against pathogens by multiple mechanisms. For example, antibodies can be 
neutralizing,(14) which means that antibodies can abolish the ability of pathogens 
to be infectious. Specifically, during a virus infection, antibodies can attach to a 
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viral attachment protein and prevent viral entry into host cells. If a virus were to 
attach, neutralizing antibodies can interfere with virus penetration and un-coating 
of the virus. Second, antibodies can bind to pathogens and attract phagocytic 
cells (macrophages) and mast cells, which can help control the pathogen. 
Thirdly, antibodies can induce antibody-dependent cell-mediated cytotoxicity 
(ADCC). ADCC occurs when virus-infected cells are coated with IgG, which 
allows NK cells to bind the Fc fragment of the antibody via Fcγ receptors. 
Crosslinking the Fc receptors signals the NK cell to kill the target cell. (11)Finally, 
antibodies coated on pathogens can activate complement-mediated lysis of 
infected cells (11). In response to viral infections, along with the mechanisms 
mentioned above, antibodies can prevent viral pathogenesis. If virus enters cells, 
antibodies can interrupt the virus life cycle within cells, such as preventing viral 
protein and ribonucleic acid (RNA) synthesis. Antibodies specific for a surface 
glycoprotein of Sindbis virus resulted in decreased viral protein synthesis and a 
cessation to infectious virion production (15). Antibodies can also make virus 
infections more severe, altering tropism by enabling the internalization of virus 
particles into various cell types. For instance, a virus that normally does not 
target macrophages would not initiate virus-specific innate responses by 
macrophages. However, specific antibody-virus complexes can be internalized 
by Fc-receptor-expressing macrophages, which can trigger a strong innate 
response against the virus. An example of this process is an antibody-dependent 
enhancement in secondary dengue infection (16).   
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E. Germ-line gene rearrangements: B cell development, CSR and SHM 
In order for B cells to recognize specific pathogens and elicit effector functions, 
BCRs must go through several germ-line gene rearrangements during 
development in primary and peripheral lymphoid organs. B2 B cells develop in 
the bone marrow (primary lymphoid organ) and then migrate to secondary 
lymphoid organs. Similar to TCR gene rearrangements, the BCR rearranges its 
heavy and light chains via VDJ recombination. BCR gene rearrangements take 
place within the bone marrow. The immunoglobulin heavy chain is rearranged 
first in the early pre-B cell stage in the bone marrow. If this rearrangement is 
successful, surrogate light chain proteins form the pre-BCR which signals to stop 
heavy chain rearrangement and to begin light chain rearrangement. There are 
two light chain genes present in mouse and humans. The kappa light chain 
rearranges first, and if unsuccessful, meaning that the rearrangement does not 
result in a light chain protein, then the lambda chain is rearranged. It is during 
these VDJ gene arrangements that the variable region of the antibody is 
generated. Once heavy and light chain gene rearrangement has successfully 
occurred, then the immature B cell, which expresses IgM goes through central 
tolerance (11, 17). Central tolerance is a process that takes place during B cell 
development in the bone marrow. Immature B cells that recognize self-antigens 
with high affinity are deleted or changes occur to BCR specificities. Immature B 
cells that strongly react to self-antigens have four end-fates: clonal deletion, 
receptor editing, anergy or immunological ignorance. The B cells that survive 
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central tolerance can migrate out of the bone marrow. In the periphery, B cells 
further mature through two transitional stages (T1 and T2), which results in 
surface expression of IgD on mature naïve B cells. (11, 18)  
B cells coming out of the bone marrow express IgM, and express IgD as 
they mature. Once activated through the BCR, B cells lose IgD expression and 
can express IgM or undergo class switching and secrete different antibody 
isotypes. The cytokine environment and T cell help dictates which isotype(s) the 
B cells will generate. Class switch recombination (CSR) is a change in the 
constant region of the antibody heavy chain. Activation-induced cytidine 
deaminase (AID) is required for CSR (19). Changes in the constant region of the 
heavy chain results in a switch in the class of antibody, generating various 
isotypes such as IgG1, IgG2a, IgG2b, IgG3, IgA or IgE (18, 20). CSR requires 
germ-line (GL) transcription at the targeted constant region of the antibody to 
activate specific isotype promoters in response to cytokines, antigen and other 
co-stimulatory signals. In vitro models have shown that cytokines, along with 
LPS, can direct the generation of specific isotypes by regulating the expression 
of GL transcripts (GLTs) (20). IL-4, transforming growth factor-beta (TGF-β ), and 
IFNγ can regulate specific isotype production. IL-4 induces the production of 
IgG1, IgG4 and IgE. Adding IFNγ, in addition with LPS, produces high levels of 
IgG2a. B cells stimulated with TGF-β can generate IgA (20). The variable region 
of antibodies is further mutated through somatic hypermutation (SHM), which can 
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help generate antibody with higher affinity for antigen. CSR and SHM occur 
during a GC response in a TD B cell response. 
F. TD B cell response: GC reaction 
GC B cell responses are generated with the help from CD4 T cells. GC 
responses are necessary for the generation of high affinity, class switched, long-
lived plasma cells and memory B cells.  
 GC are formed in secondary lymphoid organs such as the spleen and 
lymph node. GC are developed when antigen-activated B cells, along with help 
from CD4  cells, seed within the center of the follicle. Once the GC matures, two 
major compartments are formed: the light and dark zones. The light zones are 
found within secondary lymphoid organs, towards the outer portion of the GC 
follicle, near the source of antigen, while the dark zones are found within the 
inner zones of GC follicle. The dark zone consists of centroblasts (proliferating 
GC B cells) and the light zone is made up of centrocytes, which are GC B cells 
that can further differentiate into long-lived PCs, and Bmem cells. The light zone 
contains follicular dendritic cells (FDCs) and GC T follicular helper cells (GC TFH 
cells) (21, 22). FDCs can bind large quantities of antigen in immune complexes, 
through which GC B cells test BCR binding affinity to antigen. Generally, 
proliferation and SHM occurs in the dark zone, while the GC B cell selection 
based on affinity maturation and further differentiation happens in the light zone. 
GC B cells can migrate between the dark and light zones of the GC (22). GC B 
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cell selection is important for the selection of high affinity B cells that will form the 
long-lived PC and memory B cell populations. 
Plasma cells can be generated at multiple stages following a B cell’s 
encounter with antigen. B cells can differentiate into extrafollicular plasma cells 
upon initial encounter with antigen, generating short-lived plasma cells. 
Alternatively, activated B cells can migrate within the B cell follicle and generate 
GC responses. GC B cells are seen in mice starting around 5-6 days post 
exposure to antigen. Once the GC has formed, proliferating B cells (early G1 
phase) first enter the dark zone in response to the chemokine stromal cell-
derived factor-1 (SDF-1 ) that attracts (C-X-C motif)-chemokine receptor-4 
(CXCR4) positive B cells. After hours in the G1 phase in the dark zone, B cells 
(centroblasts) begin to downregulate CXCR4. Then, (C-X-C motif)-chemokine 
receptor-5 (CXCR5) upregulation allows GC B cells to migrate into (C-X-C motif)-
chemokine-13 (CXCL13) positive, FDCs-rich light zones. It is thought that 
centroblasts have low levels of surface Ig (BCR), while centrocytes increase their 
surface Ig expression. Also within the light zones, the BCR is further mutated in 
the Ig variable region through SHM creating B cells with varying affinities for 
antigen. GC B cells scan FDCs, binding antigen, and then go through a GC B cell 
selection process by presenting antigen to GC TFH cells (23). Centrocytes with a 
low-affinity BCR that triggers inadequate BCR signaling after antigen exposure or 
harbor a self-reactive BCR are induced to undergo apoptosis. GC B cell 
apoptosis occurs in a Fas-FasL dependent manner (24). Thus, some important 
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markers that are used to identify GC B cells are Fas(25), GL-7 (a T and B cell 
activation marker) (26) and peanut agglutinin (PNA). B cells that have high 
affinity or strong BCR signaling for antigen will survive and further differentiate 
into long-lived plasma cells or memory B cells. (22) Memory B cells can also 
differentiate into plasma cells upon re-encountering the same antigen. 
 It is not clear what differentiates short-lived plasma cells from long-lived 
plasma cells. However, there is a transcriptional program that dictates the 
formation of all forms of plasma cells (27). (Figure 1.2) Transcription factors 
paired box protein-5 (PAX5), microphthalmia-associated transcription factor 
(MITF), B cell lymphoma 6 (Bcl-6) and metastasis-associated 1 family, member 3 
(MTA-3) can play a role in inhibiting plasma cell development. PAX5 is required 
for B cell development and for GC responses, but it inhibits X-box-binding protein 
1 (XBP-1), which is highly expressed in plasma cells. Bcl-6 is required for GC B 
cell formation, but it is a negative regulator of B lymphocyte-induced maturation 
protein 1 (Blimp-1), a transcription factor crucial for plasma cell development. 
Bcl-6 and MTA3 can work together to mediate the repressive activity of Bcl-6 
(27). 
 The generation and preservation of GC responses require different 
molecules and cell populations. Bcl-6 is a transcription factor that is  
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Figure 1.2- Gene expression program in GC B cells and plasma cells  
 
 
GC B 
cell 
!"#$%
&'()%
*+,-.%
/0"1%
/&0(%
"&2%
Plasma 
Cell 
#*!-3%
*,456-3%
&'(7%
8#8'$9%
&:-7;%&:-<3%
0(=%+>,,?;%827@%
8#8'79%AB%8#8'19%
0C(;%&:-$;%&:-.;%&:-<3%
*%+>,,%?DBE4EF,%GF+HAB?I%*"((%FJK%"!'&:%
B cell follicle 
PC survival niches: 
Bone marrow or inflammatory 
regions 
 
Figure 1.2: Differentiation of GC B cells into PC requires a unique gene 
expression profile. Transcription factors that are important for GC B cells need to 
suppress factors required for PC differentiation. Certain chemokine receptors and 
cytokines also attract B cells into either the B cell follicle or PC survival niches. 
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essential for the generation of GC B cells (28). The formation and maintenance 
of GC depend on signals from helper T cells and CD40. Specialized 
CD4+ T cells known as TFH cells are required for the maintenance of GC 
responses. TFH cells will be discussed in more detail in the T cell section.  
TFH cells provide costimulatory signals such as CD28 and inducible T-cell co-
stimulator (ICOS). Cytokines secreted by helper T cells such as IL-4 and IL-21 
are required for preserving the GC response. CD40-CD40 ligand interactions are 
crucial because CD40 signaling induces AID expression, as does IL-4 signaling. 
CD40 also helps GC B cells survive by increasing expression of anti-apoptotic 
molecule, B cell lymphoma-extra large (Bcl-xL). GC TFH cells, fully differentiated 
and a specialized form of TFH cells present in the GC, help in the survival and 
selection of high affinity centrocytes (GC B cells located in the light zone of GCs), 
preserve the GC response by recycling some centrocytes into centroblasts by 
providing signals that can lead to the differentiation of long-lived plasma cells and 
Bmem cells. (18, 20, 22) 
 
G. Two forms of B cell memory: Long-lived Plasma Cells and Memory B 
cells 
Long-lived plasma cells and memory B cells maintain serological memory. Long-
lived plasma cells and memory B cells are both derived from GC B cell 
responses (18, 22, 29). Long-lived plasma cells reside in the bone marrow and 
continuously secrete antibody. Long-lived plasma cells can provide protective 
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antibody responses for a long duration, in many cases for a lifetime. Upon 
lymphocytic choriomeningitis virus (LCMV) Armstrong infection, mice can 
generate protective antibody responses that last one-year post infection. (30) 
Long-lived PCs express the transcription factor, Blimp-1, and CD138, also known 
as syndecan-1. (18, 31)   Memory B cells can be found in secondary lymphoid 
organs such as the spleen, lymph node or Peyer’s patches. When memory B 
cells re-encounter antigen, these cells can differentiate into plasma cells and 
secrete antibodies at a faster rate. Human memory B cells are defined by high 
CD27 expression, but there is no known marker that defines murine memory B 
cells (32). For this reason, I developed an adoptive transfer assay that can detect 
memory B cells based on their recall function. This assay will be discussed 
further in the materials and methods section. 
It is not clear what signals are required for the differentiation of GC B cells 
into either long-lived plasma cells or memory B cells. Many groups have 
generated different models to understand this differentiation process. Some 
believe that the generation of long-lived plasma cells and memory B cells is a 
stochastic, random mechanism (24). Evidence against the stochastic model 
shows that the over-expression of Bcl-2, an anti-apoptotic factor, in B1 B cells 
leads to memory B cell differentiation in a GC-independent manner (33). This 
suggests that over-expression of an anti-apoptotic factor can change the output 
of plasma cells and memory B cells (33). Studies have suggested that the 
development of long-lived plasma cells and memory B cells is dependent on the 
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affinity of their receptors. Long-lived plasma cells have been shown to have high 
affinity receptors, while memory B cells can have low affinity receptors. Memory 
B cells can be of low affinity, un-switched and appear earlier than long-lived 
plasma cells (24). It was also reported that the quality and quantity of signals 
from GC TFH cells to GC B cells could determine GC B cell fates (34). For 
instance, T cells were shown to polarize to sites where MHC:peptide complexes 
were abundant. Thus, those GC B cells that have high affinity for antigen can 
more frequently present to GC TFH and receive signals for their differentiation 
than GC B cells that have low affinity for antigen (34). Other studies have shown 
that CD40L signaling is important for memory B cell formation, but not for long-
lived bone marrow plasma cells, suggesting that different signals from helper T 
cells can influence the fate of a GC B cell (35). 
 Even though the exact mechanism of how GC B cells choose their fate is 
unclear, several different molecules have been found to be important for the 
maintenance of long-lived B cell populations. Transcription factors Bcl-6 and 
Pax5 need to be suppressed in order for GC B cells to begin to differentiate into 
long-lived plasma cells. (18) In addition to Blimp-1 and XBP-1, plasma cell 
survival requires other signals including cytokines (tumor necrosis factor(TNF), 
IL-5, IL-6, IL-21), chemokines, and B cell survival factors, B cell activating factor 
(BAFF) and a proliferation inducing ligand (APRIL). BAFF and APRIL bind, with 
different affinities, to the B cell maturation antigen (BCMA) receptor, BAFF-
receptor and transmembrane activator and calcium-modulator and cyclophilin 
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ligand interactor (TACI). (Figure 1.2) These B cell survival factors have different 
roles in promoting B cell activation and function and also in prolonging the 
persistence of plasma cells in the bone marrow. (36) It has also been shown, in 
an influenza virus (flu) model, that long-term antibody responses in mice require 
TACI. (37) 
IL-6 may help in activating PR domain zinc finger protein 1(Prdm1), the 
gene that encodes Blimp-1. The migration of plasma cells to the bone marrow 
requires signals from chemokines such as CXCL12. Reduced expression of 
CXCR5 and the up-regulation of CXCR4 and CXCR3 are essential for plasma 
cells to migrate to their survival niches. CXCL9, CXCL10 and CXCL11 are 
ligands for CXCR3, while CXCL12 attracts CXCR4 expressing cells. CXCR3 is 
up-regulated on plasmablasts in the presence of inflammatory cytokines such as 
IFNγ (18). CXCR3 plays a role in recruiting B cells to inflamed tissues. CXCL12 
is secreted by the stroma in the bone marrow and also by the red pulp within 
spleens, which attract post-GC B cells to the bone marrow or other lymphoid 
organs such as the spleen. In the absence of CXCR4, plasma cells are not 
detected in the bone marrow. (18, 29) Endothelial-cell selectin (E-selectin) ligand, 
platelet selectin (P-selectin) ligand, and CD44 have been shown to be important 
adhesion molecules on plasma cells. (18) These adhesion molecules help traffic 
the plasma cells to their survival niches: either inflammatory regions (for example 
inflamed synovial tissue) or the bone marrow. Once in the bone marrow, long 
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lived plasma cells are provided with survival signals from the bone marrow 
environment.  
All of the above mentioned interactions and steps are necessary for the 
formation and maintenance of naturally functioning B cell memory (23). TD B cell 
responses not only require helper CD4 T cells but also signals from innate 
receptors such as TLRs. TLR signaling can be important for long-lasting TD and 
TI B cell responses. In the next two sections, the role of T cell help and TLR 
signaling in mediating B cell responses will be further discussed. 
 
H. Role of T cell help for TD B cell responses-TFH cells 
CD4 T cells are a heterogeneous population of T cells which recognize antigen in 
the context of MHC class II  (major histocompatibility complex class II ) and 
respond by secreting a number of different cytokines. Unlike CD8 T cells, CD4 T 
cells are rarely associated with cytolytic function. However, they do play a role in 
supporting CD8 T responses and B cell differentiation into GC B cells and 
subsequently memory B or plasma cells (38). 
Naïve CD4 T cells can differentiate into various T helper (Th) cell subsets 
depending on the antigen stimulation and cytokine environment (39). Each of the 
CD4 helper subsets are defined by a unique master transcription factor that 
dictates the helper T cell lineage (40). IFNγ and IL-12 trigger naïve CD4 T cells to 
differentiate into Th1 cells, which secrete IFNγ, lymphotoxin α, and IL-2 (38). Th1 
cells up-regulate a transcription factor, T-bet. Th2 cells differentiate in the 
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presence of IL-4 and IL-2 and up-regulate the transcription factor GATA-3. The 
signature cytokine secreted by Th2 cells is IL-4, but IL-5, IL-13, IL-25 and IL-10 
can also be generated (39). Th1 cells provide defense against intracellular 
pathogens, while Th2 cells against extracellular parasites. Other T helper cell 
populations include Th17 cells and inducible T regulatory cells (iTregs). Th17 
cells are generated by the presence of TGFβ, IL-6, IL-21 and IL-23. Th17 cells 
up-regulate the transcription factor, RORγt and produce IL-21, IL-17α and IL-22 
(41). iTregs are developed by TGF-β and IL-2, up-regulate FoxP3 and secrete 
TGF-β, IL-35 and IL-10. iTRegs play an important role in immune tolerance (38, 
42). 
A distinct subset of CD4 T cells with a unique phenotype and cytokine 
production was identified in the GC of human tonsils (43). TFH cells are 
specialized to help generate and maintain the GC B cell response. GCs will 
develop and begin forming the dark and light zones but, without the help from 
TFH cells, the GC falls apart (22). TFH cells also provide important co-
stimulatory and differentiation signals to GC B cells as previously described. 
TFH cells have been studied in both humans and mice. Human TFH cells 
express certain markers that are not expressed by mouse TFH cells, such as 
CD57 (21, 22). In humans and in mice, there are multiple different types of TFH 
cells and these are described by their unique location in the interfollicular zone, 
within the follicle or within the light zone of the GC (44). Different TFH cells are 
also defined by various cytokine production (21, 23). Expression of CXCR5, Bcl-6 
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(45) and the ability to help GC B cells during TD B cell responses are common 
features of human and mice TFH cells (28). 
Many of the molecules expressed on TFH cells that are important for B 
cell help are expressed by all T helper cells (e.g., CD40L), but TFH cells also 
express transcription factors and chemokine receptors which distinguish them 
from other helper T cells. CXCR5+ CD4 T cells express a gene profile that is 
distinct from Th1 and Th2 cells (46). Th1 and Th2 cells can also provide some 
help to B cells, but TFH cells have a unique role in maintaining TD GC B cell 
responses (21, 44). 
 TFH cells express important co-stimulatory molecules necessary for GC 
B cell survival and differentiation such as CD40L and ICOS. In the absence of 
CD40-CD40L or ICOS or ICOSL, GC are not developed (47). Upon activation, 
TFH cells also secrete cytokines including IL-10, IL-21 and IL-6. IL-10 is an 
important growth and differentiation factor for B cells in humans and is secreted 
upon activation of ICOS signaling (48). In the absence of both IL-6 and IL-21, 
virus-specific antibody responses are abolished. IL-6 plays an important role in 
the differentiation of plasmablasts, mainly of extrafollicular B cells, and also helps 
up-regulate Blimp-1. IL-21 is important for plasma cell differentiation from GC B 
cells (49). 
Bcl-6, a transcriptional repressor, is one factor that defines TFH cells (45). 
The expression of Bcl-6 is tightly regulated and mainly expressed in GC B cells 
and TFH cells. Bcl-6, within B cells, is the transcription factor that determines a 
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GC B cell lineage commitment. Bcl-6 also negatively regulates Blimp-1. The 
dynamics between these two opposing transcription factors determine a GC B 
cell fate or a long-lived plasma cell-lineage commitment. (28, 31, 50)  
TFH cells also express high levels of signaling lymphocytic activation 
molecule (SLAM)-associated protein (SAP). SH2 domain-containing protein 1A 
(SH2D1A) encodes SAP, a 14kDa adaptor protein (51). The association of SAP 
with SLAM family receptors is central for its function as an adaptor molecule (51). 
The SLAM family includes Ly9, Ly108, CD84, 2B4, CRACC and SLAM (CD150), 
each of which is expressed on T cells, B cells, macrophages and dendritic cells 
(51). SAP-deficient (SAP -/-) mice lack natural killer T (NKT) cells, have impaired 
NK cell and cytotoxic T lymphocyte (CTL) cytolytic activity, are reduced in Th2 
type cytokine production, have major defects in the formation of GCs and have 
reduced long-term humoral immunity (3, 51). SAP-/- mice acutely infected with 
LCMV show comparable levels of IgG+CD138+ plasma cells compared to wild 
type mice (52). However, at day 30 post LCMV infection, SAP-/- mice have 
approximately 150 fold fewer LCMV-specific memory B cells per spleen than a 
WT mouse under the same conditions (52). This indicates that SAP -/- mice are 
incapable of developing or maintaining a long-term humoral response against 
LCMV. Thus, the role of SAP within TFH cells is crucial for normal GC B cell 
responses in a TD-manner. TFH cells can express other molecules as well such 
as PD-1. Staining with antibodies against P-selection glycoprotein ligand 1 
(PSGL-1) and Ly6C, a hematopoietic cell differentiation antigen, can also be 
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used to detect TFH cells. PSGL-1lo and Ly6Clo splenocytes expressed TFH cell 
markers such as CXCR5, ICOS and PD-1 (53).  
The exact mechanism required for TFH cell differentiation is still unclear. 
As mentioned before, the cytokine environment and co-stimulatory signals 
provided by antigen presenting cells can help differentiate naive CD4 T cells into 
various T helper cells. It is not clear whether the TFH cells are a unique lineage 
or if they differentiate from Th1 or Th2 polarized cells (21). IL-6 and IL-21 are 
necessary but not sufficient for the generation of TFH cells indicating there are 
other cytokines that are required for TFH cell development (49).  
It is believed that interactions with B cells are also necessary for the 
generation and full differentiation of TFH cells. CD4 T cells transferred into B cell 
KO mice (µMT KO) were not able to differentiate into TFH cells, suggesting a 
major role of B cells in TFH cell development. (31) Furthermore, the absence of 
ICOS-L (ligand) hinders TFH cell development. The expression of ICOS-L on B 
cells is regulated by the noncanonical NF-κB pathway that is induced upon the 
activation of the BAFF receptor on B cells (54). In the absence of an important 
signaling component within the noncanonical nuclear factor-kappa B (NF-κB) 
pathway (Nuclear factor kappaB-inducing kinase (NIK) knockout mice), there are 
defects in the development of TFH cells. TFH cell defects were absent upon the 
delivery of recombinant ICOS-L to NIK KO animals (54). Thus, B cells play an 
important role in the generation of TFH cells.  
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I. Role of TLRs in B cell responses 
 TLRs play an important role in innate and adaptive immune responses. 
The precise role of these innate receptors in mediating long-term antiviral 
protection was further investigated in this thesis.  
TLRs are innate receptors that recognize pathogens by detecting 
pathogen-associated molecular patterns (PAMPs) (55, 56) Twelve mammalian 
TLRs have been identified which recognize specific ligands and activate 
downstream adaptor proteins. TLRs recognize various types of ligands and can 
be found in different cellular locations. Some TLRs are found on the surface of 
cells (TLRs 1/2, 4,5,6,8,10,11,12) and others in endosomes (TLRs 3,7 and 9). 
The sensing domain of extracellular or endosomal TLRs contains leucine-rich 
repeats (LRRs), a transmembrane region and a cytoplasmic domain. LRRs fold 
into a sickle-shape sensing particular ligands. (57, 58) Some surface TLR ligands 
identified thus far include triacylated lipoproteins (TLR1/2), diacylated lipoproteins 
(TLR2/6), LPS (TLR4) and flagellin (TLR5). Some surface TLRs are also able to 
sense viral proteins. For example, TLR2 and TLR4 can recognize viral protein 
from CMV, HSV-1, and measles virus (16). Endosomal TLRs are nucleic acid 
sensors that recognize single-stranded ribonucleic acid (ssRNA) (TLR7), double-
stranded ribonucleic acid (dsRNA)(TLR3), and cytosine-phosphate-guanine 
(CpG)–rich deoxyribonucleic acid (DNA) (TLR9) (57). (Figure 1.3) 
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Figure 1.3- Schematic of TLR signaling pathway 
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Figure 1.3: Most of the TLRs signal through MyD88, IRAK, TRAF proteins, and 
the IKK complex to activate NF-kB and IRFs. 
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Upon ligand engagement, TLRs activate downstream adaptor proteins, 
such as MyD88, that mediate signaling downstream resulting in activation of 
transcription factors such as NF-kB, mitogen-activated protein (MAP) kinases 
and interferon regulatory factors (IRFs). The activation of these transcription 
factors results in the production of inflammatory cytokines (e.g. IL-1, IL-12, IL-6, 
and TNF) or type I interferon (IFN). (55, 59) (Figure 1.3) 
 IRFs are a family of transcription factors. Various IRF molecules can form 
homodimers or heterodimers upon activation that can regulate type I interferon 
responses and activate other IFN-induced genes or inflammatory responses. 
There are 9 IRF genes, two of which, IRF3 and IRF7, have been found to have 
an important role in type I interferon production. IRF7 primarily is involved in 
interferon alpha (IFNα) production (60). In addition to innate responses, IRF4 and 
IRF8 are essential for B cell activation and differentiation. IRF8 is expressed in 
GC B cells, whereas IRF4 is essential for the generation of plasma cells. (Figure 
1.2) However, the role of IRF5 in B cells is not well understood. IRF5 is activated 
by its interaction with a complex that consists of MyD88 tetramers, interleukin-1 
receptor-associated kinase 1 (IRAK1), IRAK4, and tumor necrosis factor receptor 
(TNFR)-associated factor 6 (TRAF6) following TLR activation (61). Besides 
MyD88, IRF5 can also be activated by TANK binding kinase-1 (TBK-1). Once 
activated, IRF5 can form homodimers, translocate into the nucleus and activate 
transcription of type I interferon and inflammatory cytokines (62). Unlike IRF3 and 
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IRF7, IRF5 is primarily involved downstream of TLR-MyD88 pathways such as 
TLR7 and TLR9 pathways (62, 63) (64). 
Within DCs, activation of specific TLRs and transcription factors leads to 
the production of inflammatory cytokines, dendritic cell migration to lymph nodes, 
increased antigen presentation, and up regulation of co-stimulatory molecules 
resulting in normal T cell priming and activation (56). It has been shown that in 
the absence of MyD88, in response to TLR4 ligands, DCs can still induce NF-kB 
and certain IRFs, but inflammatory cytokines are not generated (55). Thus TLR4 
can signal both in a MyD88-dependent and independent fashion. 
Some TLRs can activate NF-kB and induce IFNα and IFNβ in a MyD88-
independent manner. TLR4 can signal through other adaptor proteins known as 
TIR domain containing adaptor protein (TIRAP, also known as MAL), TIR domain 
containing adaptor-inducing IFN (TRIF), and TRIF-related adaptor molecule 
(TRAM). (65) TLR3 is the only TLR that does not signal through MyD88, but 
signals only through TRIF. TRIF can form a complex with certain kinases such as 
TBK-1 and IkappaB kinase-epsilon (IKKε) and other proteins such as TRAF3 that 
can help induce IRF3, IRF7 or NF-kB (55, 65).  
TLR signaling can affect B cell activation indirectly and directly. The 
absence of MyD88 leads to poor GC responses in response to HSA-LPS and low 
antibody production in response to various antigens such as flagellin. (66) This 
suggests that TD B cell responses not only require help from CD4 T cells, but 
may also require intact TLR signaling within B cells. It has been shown that TLR 
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signaling in B cells affects antibody class switching and also enhances antigen 
presentation by B cells (66). The importance of TLR-MyD88-mediated signaling 
for antigen-specific B cell responses to autoantigens that respond to TLR ligands 
and to other inert antigens such as ovalbumin (OVA) conjugated to LPS, and 4-
hydroxy-(3-nitrophenyl)-acetyl-conjugated to chicken gamma globulin (NP-CGG) 
in alum has been shown (67). An immune response to a virus infection is 
different from an immune response generated by a protein antigen. In a flu 
model, it was shown that MyD88 signaling was important for generating flu-
specific IgG2a responses (68). Furthermore, in other studies, B cell deficient 
mice reconstituted with MyD88-/- B cells failed to produce virus-specific IgG in 
response to respiratory syncytial virus (RSV) infection (69).  
These studies show that innate signaling contributes to adaptive B cell 
responses to various antigens. Several studies have described the immune 
responses that are required to control acute and chronic viral infections with high 
virus load and pathogenicity. In contrast, how immunocompetent hosts 
successfully control a low-level, persistent viral infection without causing disease 
is not well understood. To elucidate the role of innate and adaptive immune 
responses in controlling a persistent virus infection, I utilized a model of mouse 
polyomavirus (PyV) infection.  
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J. Mouse polyomavirus (PyV) infection model 
PyV, a DNA tumor virus, is a useful model to study immune responses to a low-
level, persistent infection in its natural host. PyV is a member of the 
Polyomaviridae family of viruses. Polyomaviruses share many common features 
in terms of their structure and they have strict host specificity. Polyomaviruses 
can be divided into three genera: Orthopolyomavirus, Wukipolyomavirus and 
Avipolyomavirus. Orthopolyomavirus and Wukipolyomavirus contain the 
mammalian viruses while the genus Avipolyomavirus contain the avian-viruses. 
Simian virus 40 (SV40), 4 human viruses: BK, JC, Merkel cell polyomavirus 
(MCV), trichodysplasia and spinulosa-associated polyomavirus (TSPyV), rodent 
polyomaviruses, and mouse polyomavirus are some viruses that make up 
Orthopolyomavirus. Four human polyomaviruses:, WU, KI, HPyV6 and HPyV7 
are included in the genus Wukipolyomavirus (70). 
Polyomaviruses are common among humans. Most humans are infected 
by a number of different polyomaviruses such as the JC, BK, KI, WU and Merkel 
cell carcinoma (MCV) viruses. Studies have shown similar seropositivity to BK, 
WU, KI and MCV viruses in healthy adult populations and in children under 21, 
suggesting that primary PyV exposure may occur in childhood (71). These 
infections are mostly sub-clinical and asymptomatic, but in people with severe 
immunodeficiency some human polyomaviruses (BK, JC and MCV) can cause 
severe pathology. For example, BK virus has been shown to be associated with 
the failure and rejection of kidney transplants (72) and with BK virus-associated 
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nephropathy in patients receiving immunosuppressive drug treatment (72). JC 
virus has been associated with progressive multifocal leukoencephalopathy 
(PML) under immune suppressive conditions (73-75). Of note, MCV is different 
from other human polyomaviruses as it is close to mouse PyV in phylogeny. 
Thus far, MCV is the only PyV directly linked to tumor formation in humans (76).    
Mouse polyomavirus (PyV) was the first polyomavirus discovered as the 
agent responsible for inducing multiple (‘poly’) tumors (‘oma’) in mice (77). This 
thesis will refer to mouse polyomavirus as ‘PyV’. PyV is a natural pathogen of 
mice, and causes a persistent infection in immunocompetent mice characterized 
by low-level virus replication. PyV was first discovered when neonatal mice were 
infected with cell extracts from leukemic tissue taken from murine leukemia virus-
infected mice (78). The surprising finding that the neonate mice developed 
salivary gland tumors suggested a tumor-inducing agent within this extract which 
was later identified as PyV (78).  
Mouse PyV, similar to other polyomaviruses, is a small, icosahedral 
shaped (40-50 nanometer in diameter), nonenveloped, double-stranded DNA 
(dsDNA) virus. The PyV genome is circular, 5.3kb in length, encodes 3 regulatory 
proteins: large T, middle T, small T, and 3 structural late proteins: viral protein 1 
(VP1), viral protein 2 (VP2), and viral protein 3 (VP3) (79). VP1 is the major 
protein that makes up the PyV capsid. Small, middle and large T antigens are 
essential for the viral life cycle, and they also interact with growth signaling 
pathways that can help promote tumorigenesis. The large T antigen is important 
31
in initiating DNA replication. Large T antigen can also interact with the product of 
the retinoblastoma susceptibility gene, pRB, and drive a resting cell into the S 
phase of division. The small T antigen can help maximize viral replication by 
interacting with protein phosphatase 2 (PP2A). Small T antigen can inhibit the 
enzymatic activity of PP2A, resulting in overactive AKT or phosphatidylinositol 3-
kinase (PI3-K) signaling pathways resulting in cell proliferation. The middle T 
antigen of mouse PyV, known as the transforming protein, interacts with cellular 
proteins (pp60 of the c-src family) and affects cell growth signaling pathways 
(80).   
PyV infection can cause tumors in different organs due to the ability of 
PyV to infect various cell types. PyV can infect and replicate within the nucleus of 
monocytes, macrophages, dendritic cells, fibroblasts and epithelial cells (81). 
Unlike certain human polyomaviruses, mouse PyV has not been shown to be 
able to replicate within lymphocytes such as B and T cells. Infectious virus and 
genome copies of PyV DNA can be found in tumor tissues. Within cells, PyV 
genome can be maintained episomally or can integrate within host DNA. 
 PyV interacts with receptors containing sialic acid for the linkage of PyV 
to host cells. Specifically, mouse PyV can use α2,3-linked sialic acid-containing 
structures as receptor for attachment to cells (82). Also, other receptors such as 
sialic acid-containing gangliosides and α4β1 integrin receptor can be used as co-
receptors for the attachment of mouse PyV to cells. (82-84) Since 
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sialoglycoproteins are ubiquitously expressed, PyV can infect a broad range of 
cell types.  
 
K. Immune control of persistent virus infections in mice 
A collaboration of innate, T cell, and B cell responses are necessary for effective 
long-term control of persistent viruses. Innate responses delay virus replication 
and spread and they also help shape the adaptive immune responses. Innate 
signals from antigen presenting cells, such as dendritic cells (DC), provide co-
stimulatory signals and generate a cytokine environment that influences the 
appropriate antiviral adaptive response. The adaptive response provides viral 
antigen specificity and memory. Different infections involve various mechanisms 
that are important in viral control or clearance. Some viral infections such as 
MCMV greatly depend on innate cells such as NK cells, but other components of 
the immune system are still required for complete control. Other viral infections 
such as LCMV strongly rely on the cytolytic activity of CD8 T cells (85). Humoral 
immunity can also be important in the clearance of some acute viral infections 
such as Sindbis virus, and plays an important role in maintaining life-long 
protection in many virus infections (15). 
L. Immunological control of PyV infection 
An important consequence of impaired control of PyV infection is tumor 
formation. Immunocompetent adult mice are resistant to PyV-induced tumor 
formation after PyV infection regardless of their genetic background. Certain 
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strains of mice such as C3H or Balb/c are susceptible to tumor formation if 
infected as neonates. B6 mice have been known to be resistant to PyV-induced 
tumors (86). Neonates of certain susceptible strains infected with PyV develop a 
variety of tumors of mesenchymal and epithelial origin later in life (2, 86). 
Originally the resistance of adult mice to PyV-induced tumors was thought to be 
due solely to the ability of PyV to grow well in neonatal, but not in adult tissues. 
Although PyV grows somewhat better in neonatal tissues than in adult mouse 
tissues(87), experiments done with SCID mice infected as adults demonstrated 
that adult mice can also support high levels of virus replication (88). Therefore, 
tumor resistance in adult mice is mainly due to both antiviral and antitumor 
immune responses. It was shown that high tumor susceptibility in some H-2k 
mouse strains that were neonatally infected is due to the presence of a 
superantigen that deletes Vβ6 CD8 T cells (89). Vβ6 CD8 T cells in H-2k mice 
have specificities for middle T antigen-derived class I epitopes on PyV-infected 
cells and PyV tumor cells (89). Thus, the absence of Vβ6 CD8 T cells makes 
mice susceptible to PyV-induced tumor formation. 
The role of CD8 T cell responses to PyV infection has been extensively 
studied. CD8 T cells have been shown to significantly control PyV-induced 
tumors (2, 90). Studies with neonatally thymectomized mice and congenically 
athymic mice have shown that T cells can prevent tumors induced by PyV. (91) 
Mice defective in MHC class I-restricted antigen presentation have an increased 
susceptibility to PyV-induced tumors (90). Studies have shown that CD8 T cell 
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protection from PyV-induced tumors is perforin-, Fas-, and TNFα- independent 
but dependent on IFNγ (92, 93). 
CD4 T cells provide help to other cells including CD8 T cells and B cells. 
The role of CD4 T cells in the maintenance of CD8 T cell responses can vary in 
different infections. During a PyV infection, CD4 T cells have been shown to be 
important for recruiting newly primed CD8 T cells during the persistent phase of 
PyV infection (94). CD4 T cell responses also seem to be important in 
maintaining antiviral antibody responses at late time points post PyV infection 
(94). 
In contrast to immunocompetent mice that can maintain a low-level of PyV 
persistence after infection and survive without disease, mice without an adaptive 
immune system succumb to PyV infection within weeks. SCID mice that lack T 
and B cells showed anemia, splenomegaly and massive myeloproliferation upon 
PyV infection (88). The acute myeloproliferative disease in these mice was due 
to uncontrolled PyV infection with very high viral loads resulting in death within 2 
weeks following infection(88). NK cell depletion did not change the outcome of 
infection and NK cells were shown not to directly regulate PyV load (88). 
 Confirming the importance of T cell responses in preventing PyV-induced 
tumors, studies have shown that PyV infection of adult TCRβδ KO mice results in 
tumor formation. Surprisingly, mice that lack β T cells (TCRαβ KO mice) but still 
have γ T cells are resistant to tumor formation after infection. (95) Furthermore, 
virus-induced tumors appear early in mice that lack NK cells and all T cells (E26 
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transgenic mice), compared to TCRβδ KO, which have NK cells and are only T 
cell-deficient. Thus, γδT cells and NK cells also contribute to the resistance to 
PyV-induced tumors and they can protect mice from tumor formation in the 
absence of T cells. (95) 
Humoral immunity is not sufficient for directly controlling PyV-induced 
tumors (2),  but antibody responses can lower PyV loads (96). TCRβδ KO mice 
infected with PyV survive 6-8 months post infection, till the time when tumors 
develop (95), while SCID mice die within 2 weeks of PyV infection (88). This 
suggests that a TI antibody response can control PyV loads and help mice 
survive in the absence of T cells (88, 96, 97).  Mice deficient in B cells (µMT 
mice) still maintain tumor resistance (98). Passive immunization with PyV-
immune serum prevented tumor formation in neonatal mice prior to PyV infection.  
However, administration of PyV-immune serum into neonatal mice after the start 
of infection did not protect mice from tumors (99).  
The majority of the antibody response to PyV is directed at the major 
capsid protein, VP1. Upon PyV infection of WT mice, IgM (immunoglobulin M) 
appears at 4 days post infection and virus-specific IgG starts to be detectable 
around 7 days post infection (3, 3, 97). The peak of the PyV load in various 
organs of WT mice such as spleen, liver, kidney and lung is 5-6 days post 
infection (2, 3). The peak of antiviral IgG antibody responses is detected between 
21-28 days post infection in WT mice (3). 
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The role of TI antibody in PyV control and protection was further 
investigated in TCRβδ KO animals. Upon PyV infection, T cell-deficient mice 
efficiently generate a TI antibody response consisting of virus-specific IgM and 
IgG, and they can survive several months post infection. (1, 96, 100) The TI IgG 
responses in T cell-deficient mice were reduced to ~ 10% from WT titers that 
were measured in mice 14 days post PyV infection (1). Of note, TI IgG responses 
primarily consisted of virus-specific IgG2a and IgG2b (4). PyV-specific TI IgG3 
was present at very low and variable levels and IgG1 was undetectable (4). T 
cell-help is known to be important for the induction of IgG1. The finding that TI 
IgG responses can confer protection from PyV infection (96) suggests that IgG2a 
and IgG2b responses play an important anti-PyV role in T cell-deficient mice. 
 PyV was defined as a T cell-independent type II (TI-2) antigen when BTK 
(bruton’s tyrosine kinase) deficient B cells transferred into PyV-infected SCID 
mice (with no T cells) could not generate an antibody response (100). BTK 
deficient cells were obtained from Xid (X-linked immunodeficiency) mice that 
display impairments in B cell receptor signaling and B cell survival (7). The PyV 
capsid, which consists of 72 pentameric capsomeres of the VP1 protein, 
represents the repetitive ligand that is capable of stimulating a TI-2 antibody 
response. Comparative studies with either VLPs (virus-like particles) given at a 
dose of 70 hemagglutination units (HAU) or live PyV infection have shown that 
live virus is needed to generate a TI anti-PyV IgM and IgG. VLPs can only induce 
IgM in TCRβδ KO mice (4). Furthermore, studies that block CD40-CD40L 
37
signaling by anti-CD40L antibodies in T cell-deficient mice or studies using 
CD40-/- mice further showed that the lack of CD40-CD40L signaling greatly 
reduces the TI anti-PyV IgG response. This suggested that in the absence of T 
cells, other cells could provide the CD40L, which plays an important role in TI 
antibody responses to PyV infection. (101) These data suggest that, in an 
immune compromised host, antibody responses, generated in the absence of T 
cells, may help control the PyV load.  
Our lab has investigated the role of the innate adaptor molecule MyD88 in 
mediating long-term TD B cell responses to PyV infection. MyD88-deficient mice 
had low levels of total virus-specific IgG starting at 2-3 weeks and lasting untill 
1.5 years (latest time point tested) post PyV infection when compared to WT 
mice (3). The isotype usage among PyV-specific antibodies in WT mice was 
primarily IgG2a with some IgG1. PyV-specific antibodies in MyD88-/- mice, at 3 
weeks post infection, were skewed towards IgG1 with low levels of IgG2a (3). In 
addition to skewed isotypes, MyD88-/- mice also had fewer (25-fold less) long-
lived plasma cells in the bone marrow than WT mice (3). To further investigate 
long-term antibody responses, GC responses were tested. It was shown that 
MyD88-/- mice can generate normal frequencies of GC B cells as WT mice at 7 
and 14 days post infection, indicating that MyD88-/- mice can initiate normal T 
cell-dependent IgG production and GC B cell responses to an acute PyV 
infection (3). Thus, MyD88-mediated pathways are not needed to initiate, but are 
required to maintain protective antibody responses to a persistent virus infection. 
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Overall, varying degrees of immunodeficiencies can lead to different 
pathologies, morbidity and mortality in response to PyV infection. The 
aforementioned information suggests that there is a complex immune response 
required for the control of this low-level persisting virus. A defect in any arm of 
the immune system can change the delicate balance between the disease-free 
host and virus replication, where increasing PyV loads result in pathology such 
as tumor formation. A strong and long-lasting humoral response is necessary to 
keep a persistent virus such as PyV controlled within hosts. Given the 
importance of MyD88 in the generation of a long-lasting humoral response, I 
sought to examine the role of innate signaling pathways in the formation and 
maintenance of long-lasting B cell responses to PyV infection. 
 
M. Thesis Objectives 
The longevity of antibody responses generated by B cells after infection, 
immunization or in the course of autoimmune diseases is of high importance.  
Life-long humoral immunity is desirable after natural infections or vaccinations to 
prevent the same kind of infection and disease for the lifetime of the host.   
At the same time, autoreactive B cell responses need to be short-lived in order to 
avoid autoimmune pathology. The goal of the work presented in this thesis is to 
understand what is required to sustain a long-term T cell-dependent (TD) and T-
cell independent (TI) antibody response to a persistent virus infection, specifically 
how innate receptors affect long-term B cell responses. To undertake this task, I 
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used mice that were deficient in one or several different toll like receptors or 
adaptors found downstream of TLRs. These studies helped identify which TLR(s) 
pathways affected long-term TD antibody responses. I also performed adoptive 
transfer experiments to examine memory B cell responses in MyD88-/- mice. 
Using mice that were deficient in IRF5, a transcriptional regulator downstream of 
the TLR-MyD88 pathways, allowed me to further unravel the mechanism behind 
the isotype antibody defects observed in MyD88-/- mice.  
TCRβδ KO mice infected with PyV are capable of generating long-lasting 
VP1 specific IgG. I wanted to examine how T cell-deficient mice were able to 
maintain long-term antibody responses to PyV without T cell help. My findings 
suggest that high antigen levels and the involvement of innate pathways lead to 
the maintenance of long-lasting antiviral IgG responses in PyV-infected TCRβδ 
KO mice even in the absence of a “TI memory” response.  
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CHAPTER II: Materials and Methods 
 
A. Mice and Infection 
All the mice used in the studies were on the C57BL/6 (B6) background. TCRαβ 
KO, TCRβδ/TCRαβγδ KO, TCRγδ KO and SCID mice were originally obtained 
from the Jackson Laboratory (Bar Harbor, Maine), and colonies of these mice 
were maintained in the Department of Animal Medicine of the University of 
Massachusetts Medical School under specific pathogen free conditions. TCRβδ 
KO/ MyD88-/- mice were bred by crossing TCRβδ KO mice and MyD88-/- mice 
and maintained at the animal facilities at the University of Massachusetts Medical 
School. MyD88-/- mice were originally provided by Dr.K. Alugupalli (Thomas 
Jefferson University, Philadelphia, PA). TLR7-deficient (TLR7-/-), TLR3-deficient 
(TLR3-/-), TLR9-deficient (TLR9-/-), TLR2-deficient (TLR2-/-), TLR4-deficient 
(TLR4-/-), IRF5-deficient (IRF5-/-), MyD88/TRIF double knockout (DKO), 
UNC93B1 deficient (3d) and TLR7/9 double deficient mice were generously 
provided by the labs of Dr. Egil Lien and Dr. Kate Fitzgerald at University of 
Massachusetts Medical School. MyD88/TRIF DKO and TLR3-/- mice were also 
provided by the labs of Dr. Susan Swain and Dr. Dick Dutton. IRF5-/- mice were 
backcrossed to C57BL/6 for 10 generations and CD11c-cre-IRF5-floxed mice 
were obtained from Dr. Egil Lien. IRF5-floxed mice were originally generated by 
Dr. Paula Pitha at Johns Hopkins. All knockout mice were maintained in the 
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Department of Animal Medicine of the University of Massachusetts under specific 
pathogen free conditions.  
Mice were used between 8 and 12 weeks of age and virus infections were 
done intranasally (i.n.) or intraperitoneally (i.p.) with ~106 PFU of PyV strain A2. 
All the procedures using animals were done according to protocols approved by 
the University of Massachusetts Medical School Animal Care and Use 
Committee. 
 
B. VP1-specific Enzyme-linked immunosorbent assay (ELISA) 
VP1-specific ELISAs were conducted as previously described (101, 102). Briefly, 
purified recombinant VP1 protein (0.1 µg/ml in carbonate buffer) was used to 
coat 96 well plates (using 50ng/well). VP1 was generously provided by Dr. 
Robert Garcea. Bound Ab was detected using biotin-conjugated goat Abs 
specific for mouse IgG; and streptavidin-conjugated HRP (Vector Laboratories). 
ELISA plates were developed using BD OptEIA TMB Substrate Set (BD 
Pharmingen), and reactions were stopped with 2 N sulfuric acid. Optical densities 
were read at 450 nm by THERMOMAX microplate reader and SoftMax software. 
Data are represented as optical density (o.d.) versus serum dilution (raw data), or 
data converted into IgG titers or shown as IgG concentration expressed in 
arbitrary units. The IgG titers represent end point titers, which are defined as the 
highest serum dilutions showing optical density in the ELISA above the values of 
negative control serum. The arbitrary units are derived from a standard curve 
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generated with various dilutions of a positive control serum in the same 
experiment. 
C. VP1-specific Enzyme-linked immunosorbent spot (ELISPOT) 
To determine the number of VP1-specific Ab-secreting cells (ASC), multiscreen 
HTS filter plates (Millipore) were coated with purified VP1 protein (0.1 g/ml in 
carbonate buffer, 50µl/well). Unlabeled goat anti-mouse Ig (H+L) (Southern 
Biotech) coated wells were used for determining total IgG ASC, and some wells 
were just coated with carbonate buffer (no coat controls). The plates were 
incubated overnight at 4°C and blocked the next day for 30 min at 37°C with 
RPMI plus 10% FBS. Cells were plated in duplicates in 0.2 ml at a concentration 
of 107 cells/ml and then followed by 2-fold dilutions. Cells were then incubated for 
4 h at 37°C. Following incubation the cells were discarded and the plates were 
washed and blocked with 1% BSA in PBS for 30 minutes at 37C. Bound Ab was 
detected using biotin-conjugated goat Abs specific for mouse IgG and 
streptavidin-conjugated HRP. Plates were developed with Elispot AEC Substrate 
Set (BD Pharmingen) according to the manufacturer’s protocol. Spots were 
counted using the CTL ImmunoSpot (Cellular Technology Ltd.). The data are 
shown as antibody secreting cell (ASC) frequencies. 
 
D. Quantitative PCR (qPCR) to measure viral DNA genome copy number 
DNA was prepared from organ homogenates by digestion with proteinase K 
(Sigma) at 55°C overnight, followed by phenol extraction and RNase-A treatment 
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(10u/µl, Promega).  The PCR amplification was performed using SYBR Green 
Master Mix Kit from (Applied Biosciences).  Briefly, 50 µl reaction mix containing 
25µl of 2X master mix, 20 pmol each of forward and reverse primer (Invitrogen), 
and 250ng of the DNA sample were used. The following primers were used: β 
actin forward CGA GGC CCA GAG CAA GAG AG; β actin reverse CGG TTG 
GCC TTA GGG TTC AG; PyV VP1 forward CCC CCG GTA CAG GTT CAG TCC 
CAT CAT; VP1 reverse GGC ACA ACA GCT CCA CCC GTC CTG CAG. The 
amplification conditions for VP1 were 95°C for 10 min, followed by 37 cycles of 
95°C for 30 sec, 65°C for 20 sec, 72°C for 45 sec.  PCR amplification with the β 
actin primers used the following conditions: 95°C for 10min, then 40 cycles of 
95°C for 30 sec, 62°C for 25 sec, and 72°C for 25 sec. Negative controls 
included a sample with no DNA substrate, and DNA from uninfected mouse 
organs. Three-fold serial dilutions of DNA prepared from uninfected mouse 
organs (starting from 750ng) were used to generate a standard curve for β actin 
PCR.  For PyV standards we used a recombinant plasmid containing the VP1 
coding sequences and made dilution series from 2x108 copies to 20 copies. All 
the reactions were run in duplicates.  The obtained PyV copy numbers were 
normalized to β actin, which reflected the amount of mouse genomic DNA 
present, and the results were expressed as PyV genome copies/ µg organ DNA. 
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E. Quantitative PCR (qPCR) to measure IRF5 transcript levels 
MACS-purified CD11c-positive and CD11c-negative cells from splenocytes were 
stimulated with IFNβ overnight. The following day, total RNA was isolated from 
these cells using the RNEasy Mini Kit; cat: 74104; Qiagen, following the 
manufacturer’s protocol. RNA concentration was determined by nanodrop. cDNA 
synthesis was performed using QuantiTect Reverse Transcription kit ( cat: 
205311; Qiagen) by following instructions provided by the manufacturer. qPCR 
was performed using the QuantiFast SYBR Green PCR kit (cat: 204054; 
Qiagen). Briefly 25 µl reaction mix containing 12.5µl of 2X master mix, 10 pmol 
each of forward and reverse primer (Invitrogen), and <100ng of the cDNA sample 
was used.  
The following primers were used: β actin forward CGA GGC CCA GAG 
CAA GAG AG; β actin reverse CGG TTG GCC TTA GGG TTC AG; IRF5 forward 
CTT CAG TGG GTC AAC GGG; IRF5 reverse TGT ACG GCT GAG GTG GCA 
T. PCR amplification with the β actin and IRF5 primers used the following 
conditions: 95°C for 5min, then 40 cycles of 95°C for 10 sec, and 60°C for 30 
sec. All the reactions were run in duplicates. β-actin was used for normalization 
and fold change was calculated using delta delta CT method (2(-ΔΔCT) ) 
 
F. Flow cytometry  
To examine the expression of cell surface markers by flow cytometry, 
splenocytes were treated with 0.84% NH4Cl to lyse RBC and then washed with 
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FACS buffer (PBS plus 1% FCS, 2 mM EDTA, and 0.02% NaN3). Cells were 
treated with purified anti-CD16/32 (Fc block; clone 2.4G2; BD Pharmingen) and 
then stained for 30 min at 4°C with Abs diluted in FACS buffer at 1:200, unless 
stated otherwise. Abs used in these studies included FITC-rat anti-mouse T and 
B cell- activating Ag GL7 (clone GL7; BD Pharmingen), PECy7-rat anti-mouse 
CD19 (clone 1D3; BD Pharmingen), PE-hamster anti-mouse CD95 (BD 
Pharmingen), Pacific Blue-rat anti-mouse B220 (CD45R) (clone RA3-6B2; BD 
Pharmingen), Alexa Fluor 647 anti-Bcl-6 (clone K112-91; BD Pharmingen), PE-
anti-mouse Bcl-6 (clone mGI191E; ebioscience, used at 1:100), APC Rat anti-
mouse CD184/CXCR4 (clone 2B11/CXCR4; BD Pharmingen), PE-Cy7-Rat anti-
mouse CXCR5 (clone 2G8; BD Pharmingen, used at 1:50 in room temperature), 
PecrcpCy5.5- anti-mouse CD279 (PD-1) (clone 29F.1A12; biolegend), Alexa 700 
anti-mouse CD4 (clone RM4-5; BD Pharmingen), Pacific blue- anti-mouse CD3ε 
(clone 145-2C11; BD Pharmingen), PE-Cy5-anti-mouse CD278 (ICOS) (clone 
7E.17G9; ebioscience), APC-anti-mouse/rat FoxP3 (clone FJK.16s; 
ebioscience), PE-Rat anti-mouse CD162/PSGL-1 (clone 2PH1; BD Pharmingen), 
and FITC-Rat anti-mouse Ly-6C (clone AL-21; BD Pharmingen) Flow Cytometry 
Analysis: at least 100,000 events were counted using a LSRII (BD Biosciences) 
and analyzed using FlowJo software (Tree Star). 
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G. Intracellular staining (ICS) 
Cells were prepared as described in part I. Surface staining of cells was 
performed first, following the surface stain, cells were permeabilized using the 
FoxP3 Ebioscience kit. For 2-21/2 hrs at 4C. Cells were washed and blocked 
again with Fc block for 5-10 min at room temperature. Following blocking and no 
intermediate wash step, antibodies against nuclear proteins such as Bcl-6 and 
FoxP3 were added in Perm Buffer for 20-30 min at 4C. Following intracellular 
staining, cells were washed twice with perm buffer and twice with FACS buffer. 
Cells were resuspended in 250ul of FACS buffer and ran on the LSR II. 
 
H. B cell memory assay 
Spleens were harvested from uninfected and PyV-infected TCRαβ KO, TCRγδ 
KO, TCRβδ KO, MyD88-/-, and wild type B6 mice. SCID recipients were given107 
splenocytes intravenously. Following 1-day post cell transfer, some of the SCID 
mice in each group were infected with PyV (~106 pfu intraperitoneally). Five to 7 
days post infection, VP1 specific Elisa was performed to detect recall IgG 
responses from the sera of SCID mice. 
 
I. Preparation of cells 
Single cell suspensions were made from spleens, peripheral blood or bone 
marrow. For all cases, using .84% NH4Cl solution lysed red blood cells. Spleens 
were homogenized in RPMI1640 (Invitrogen) and then filtered through nylon 
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mesh. Blood for cells was taken from tail vein in heparinized tubes, however 
blood for serum was taken in non-heparinized tubes and spun at 5500rpm for 5 
min to collect serum. Bone marrow was taken by removal of the femur and tibia 
bones from both legs and flushing of the bone marrow from the bones using 
RPMI1640 and a 10 mL syringe. RPMI1650 was supplemented with 10% FCS, 
LG and PS.  
For adoptive transfer experiments, cells were washed re-suspended in HBSS 
(Hank’s Balanced Salt Solution) and transferred into recipient mice intravenously 
at 10^7 cells/ml. 
 
J. MACS enrichment and adoptive transfer of cells 
Spleens cells harvested from Ly5.1 B6 mice were pooled and treated with 0.84% 
NH4Cl to lyse RBC and then re-suspended in MACS buffer as instructed by the 
various manufacturer protocols (Miltenyi biotec MACS kit). CD8 T cell isolation kit 
(Miltenyi biotec,) for negative selection of CD8 T cells was used to purify CD8 T 
cells from the splenocytes. Pan T cell isolation kit II (Miltenyi biotec; 130-095-
130) was used to purify all mouse T cells by depletion of non-T cell targets. Pan 
B cell isolation kit (Miltenyi biotec; 130-095-813) was used for the negative 
selection of all mouse B cells. CD11c mouse microbeads (Miltenyi biotec; 130-
052-001) were used to enrich CD11c+ cells from splenocytes. FACS analysis 
was performed before and after MACS selection on the splenocytes.  
48
Adoptive transfer of cells: Cells were re-suspended in HBSS and intravenously 
transferred into recipient mice. For CD8 T cell transfer experiments, 7x106 cells 
were intravenously (i.v.) transferred into each of 5 TCRβδ KO mice. Purified107 
IRF5-/- or WT B cells along with 1.2 x106 WT T cells were transferred into 
RAG1/2 KO recipients i.v. 
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CHAPTER III: Role of innate signaling pathways in maintaining a long-term 
antiviral TD B cell response 
Innate immunity plays an important role in the defense against viruses, but for 
many viruses it is not sufficient to clear the infection, and adaptive immunity is 
essential for survival (for example, PyV is lethal in SCID mice) (88). Adaptive 
immunity is important to prevent reinfection, since immunological memory to 
infections is a unique attribute of the adaptive immune system. A strong and 
long-lasting humoral response is necessary to keep the virus controlled within 
hosts. Two distinct long-lived B cell populations usually manifest B cell memory: 
long-lived PC and memory B cells. Both are the products of B cell responses 
generated with CD4 T cell help. Viral infections, unlike protein immunizations 
such as NP-CGG, can induce inflammatory signals and activate innate receptors. 
Innate signals have been shown to play an important role in promoting B cell 
responses (66). Previously, our lab has shown that MyD88-/- mice infected with 
PyV generate normal acute B cell responses but have defects in long-term 
humoral immunity (3). In addition to having defects in long-term antibody 
responses, MyD88-/- mice were shown to have skewed isotype antibody 
responses to PyV. MyD88-/- mice generate normal levels of virus-specific (VP1) 
IgG1 and very low levels of VP1-specific IgG2a and IgG2b (3). Mice deficient for 
MyD88 also lack long-lived plasma cells in the bone marrow when compared to 
wild type mice (3). In addition to TLRs, MyD88 is also found downstream of the 
IL-1R (IL-1 receptor) and the IL-18R (IL-18 receptor). Previous experiments from 
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our lab showed that IL-1R KO and IL-18R KO mice had no defects in long-term 
antibody production upon PyV infection,(3) indicating that these cytokine 
receptors are not involved in the antibody defects observed in MyD88-/- mice. 
Thus, this chapter will further investigate the long-term humoral defect in MyD88-
/- mice and describe which innate signaling pathways play a role in sustaining 
long-term humoral antiviral responses. 
 
A. Diminished B cell memory responses to PyV in MyD88-/- mice 
Since our lab had previously identified a lack of long-lived plasma cells in 
MyD88-/- mice upon PyV infection, I questioned whether recall memory B cell 
responses were also impaired in MyD88-/- mice. To test B cell recall responses 
in MyD88-/- mice, I developed a functional recall memory assay. This assay was 
based on demonstrating early (day 5-7) recall IgG responses by memory B cells 
from SCID mice that were adoptively transferred with PyV-infected splenocytes. 
In these assays, SCID mice that received splenocytes from PyV-immune mice 
and were subsequently infected with PyV would give early, strong VP1-specific 
IgG recall responses. On the other hand, control groups, such as mice that 
received non-immune spleen cells, or mice that received PyV-immune 
splenocytes but were not challenged with PyV, would generate very low or 
undetectable VP1-specific IgG recall responses in their sera at this early time 
point.  In this assay, SCID mice were reconstituted with either of the following 
groups of splenocytes: naïve splenocytes from WT mice, naïve splenocytes from 
51
MyD88 -/- mice, PyV-immune splenocytes from WT mice, or PyV-immune 
MyD88-/- mice. On the day of cell transfer, some of the reconstituted SCID mice 
from each experimental group were infected with PyV, whereas others were left 
uninfected. Seven days post cell transfer and PyV infection, VP1-specific IgG 
responses were measured in the sera to determine the recall response. (data not 
shown) SCID mice given PyV-immune MyD88-/- splenocytes, along with a re-
infection, were not able to generate a strong memory B cell response, as did 
SCID mice given PyV-immune WT cells. Therefore, in addition to the reduced 
long-lived PC population in the bone marrow, MyD88-/- mice had also diminished 
B cell recall memory in response to PyV infection. 
Next, I investigated which pathways are involved in MyD88-mediated 
regulation of long-term humoral immunity to PyV. It was further examined what 
molecular mechanisms underlie the isotype skewing of the antiviral IgG 
responses of MyD88-/- mice.  
  
B. Role of TLR-MyD88 pathways in mediating anti-PyV IgG2a responses 
The major isotype that is generated in response to most virus infections in mice, 
including PyV, is IgG2a (103). Viral infection generates antiviral interferon 
gamma (IFNγ) responses, which studies have shown helps induce IgG2a (102). 
IgG2a mediates various antiviral effector functions dependent on the antigen and 
the immune environment. As mentioned before, MyD88-/- mice generate low 
levels of VP1-specific IgG2a and normal levels of IgG1 (3). WT mice, in response 
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to PyV infection, generate high levels of IgG2a and lower levels of IgG1 (3). IgG1 
and IgG2a have neutralizing properties, but these antibodies have different 
effectiveness in mediating a variety of other effector functions because of their Fc 
portions. IgG2a, via its Fc portion, can activate the complement cascade, bind to 
activating Fc receptors with high affinity (104)(106) and induce ADCC (105).  
However, the Fc portion of IgG1 interacts with a lower affinity with Fc receptors 
(106). These differences in affinities of FcγR binding of IgG2a, IgG2b and IgG1 
Fc leads to, generally, a more effective protection by antiviral IgG2a and IgG2b 
compared to IgG1 in virus-infected hosts (106)(107). 
It is important to note that C57BL/6 mice express the Igh-1b allotype, 
which is referred to as IgG2c. Other mouse strains express the Igh-1a allotype 
known as IgG2a (108). In this thesis, when describing the isotype responses, 
IgG2a will be used, although the background of the mice used is B6. Since 
MyD88-/- mice generate low levels of PyV-specific IgG2a, I investigated which 
receptors upstream of MyD88 (TLRs) are involved in mediating antiviral IgG2a 
responses. 
Endosomal TLRs (TLR 3,7/8, and 9) are known as ‘viral sensors’ and 
recognize nucleic acids. In order to investigate the role of nucleic-acid-sensing 
TLRs in the regulation of IgG2a production, we used Unc93B1 mutant mice (also 
referred to as ‘triple D’ (3d) mice). Unc93B1 is an endoplasmic reticulum (ER) 
transmembrane chaperone protein that plays an important role in the 
translocation of TLRs 3,7 and 9 from the ER into endosomes where these TLRs 
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interact with their ligands and become activated (109). Thus, a point mutation 
within Unc93B1 (H412R) abrogates its ability to traffic the endosomal TLRs,(109) 
essentially creating mice that are deficient in TLRs3, 7 and 9 signaling (110). 
3d mice generated similar levels of VP1-specific IgG1 as WT and MyD88-
/- mice at 5 weeks post PyV infection. (Figure 3.1b) However, unlike WT mice 
that generated normal VP1-specific IgG2a responses, 3d mice produced reduced 
levels of virus specific IgG2a, similar to that of MyD88-/- mice. (Figure 3.1a) 
Since 3d mice cannot signal through TLRs 3,7 and 9, we investigated these 
TLRs individually to assess if one or more endosomal TLRs are involved in 
controlling isotype responses. TLR9 recognizes CpG DNA (PyV is a small DNA 
virus) and TLR7 is known to recognize ssRNA. (55) The ligand for TLR3 is 
dsRNA and does not signal through MyD88 but signals via another adaptor 
protein known as TRIF (55). Experiments with TLR9-deficient (TLR9-/-) mice, 
TLR7-deficient (TLR7-/-) mice, and TLR3-deficient (TLR3-/-) mice did not display 
defects in VP1-specific IgG2a responses as seen in 3d mice and MyD88-/- mice. 
(Figure 3.1a-c) However, as expected, VP1-specific IgG2a responses were low 
in MyD88/TRIF double KO mice, similar to what has been observed in MyD88-/-. 
(Figure 3.1a) 
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Figure 3.1- VP1-specific isotype antibody responses are not skewed in individual 
TLR3, TLR7 and TLR9 deficient mice, only in 3d or MyD88-/- mice 
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Figure 3.1 (cont.)- VP1-specific isotype antibody responses are not skewed in 
individual TLR3, TLR7 and TLR9 deficient mice, only in 3d or MyD88-/- mice 
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Figure 3.1- VP1-specific isotype antibody responses are not skewed in 
individual TLR3, TLR7 and TLR9 deficient mice, only in 3d or MyD88-/- mice 
 
(a-b)VP1- specific IgG2a and IgG1 responses in TLR7-/- and TLR3-/- mice along 
with 3d, MyD88-/- and WTB6 mice 4 weeks post PyV infection. (c) PyV-specific 
IgG2a responses in TLR9-/- (n=4) and WT (n=2) mice 3 weeks post PyV 
infection. Mean +/- SD is shown ***p=.002, **p=.0037 
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 TLR7-/- or TLR9-/- mice did not have defect in VP1-specific IgG2a production. 
However, attenuated levels of VP1-specific IgG2a were observed in 3d and 
MyD88-/- mice, suggesting an importance of TLR7 and TLR9 in isotype 
responses to PyV infection. To evaluate the role of both TLR7 and TLR9 in 
mediating IgG2a responses, TLR7/TLR9-double deficient (TLR7/9 DKO) mice 
were infected with PyV. At 3 weeks post PyV infection, TLR7/9 DKO mice 
generated low-levels of VP1-specific IgG2a and normal levels of VP1-specific 
IgG1 when compared to WTB6 mice. (Figure 3.2a-b) All of these studies show 
that TLR7 and TLR9 are play an important role in the generation of IgG2a in 
response to PyV infection.  
 
C. Role of IRF5 in regulating B cell-intrinsic IgG2a responses  
Interferon regulatory factors are transcriptional mediators that play an important 
role in type I interferon induction, apoptosis, and antiviral immune responses 
(60). IRF4, IRF5, and IRF8 have been shown to be important in B cell responses. 
IRF4 is essential for CSR and plasma cell differentiation by regulating Blimp-1 
expression in B cells (111).Conditional deletion of IRF4 in GC B cells inhibited 
plasma cell differentiation post the GC response (111). Furthermore, IRF4 
deficient mice did not express the enzyme AID (111). IRF8 plays a role in B cell-
lineage commitment as IRF8 deficient mice have low numbers of pre-pro-B cells 
and an increase in myeloid cells (112). In B cells, IRF8 induces Bcl-6 expression 
which is important for GC B cell responses (24).   
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Figure 3.2- TLR7/9 DKO mice have a defect in the generation of VP1-specific 
IgG2a, but not VP1-specific IgG1  
 
 
 
a. 
3 weeks post PyV infection: IgG2a
Ig
G
2a
 T
ite
rs
WT TLR7/9 DKO
0
5000
10000
15000
>*
**
 
b. 
3 weeks post PyV infection: IgG1
Ig
G
1 
Ti
te
rs
WTB6 TLR7/9 DKO
0
5000
10000
15000
>* >*
 
59
Figure 3.2- TLR7/9 DKO mice have a defect in the generation of VP1-
specific IgG2a, but not VP1-specific IgG1  
 
VP1-specific IgG2a and IgG1 responses detected in the sera of WTB6 and 
TLR7/9 double deficient mice 3 weeks post PyV infection. Mean +/- SD is shown  
>* The IgG2a or IgG1 titers are equal or greater than 128000. **p value <.01 
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 IRFs, including IRF5, are transcription factors closely linked to the TLR 
pathway and therefore to MyD88. It was important to further investigate IRF5 
because it is known that IRF5 interacts with MyD88 upon TLR7 and TLR9 
activation (62). IRF5 is important in type I interferon responses, but can also 
have an antiviral role as shown by the susceptibility of IRF5-deficient mice to 
virus infections (62). IRF5 expression is induced upon viral infection or by TLR7 
or TLR9-MyD88 pathways (62, 113). Furthermore, polymorphisms in IRF5 have 
been shown to increase susceptibility to systemic lupus erythematosus (SLE) 
(114). In mouse models of pristine-induced lupus, IRF5-deficient mice were not 
able to generate anti-nuclear autoantibodies of the IgG2a isotype, suggesting 
that IRF5 may regulate IgG2a responses (115). Stimulating IRF5-deficient (IRF5-
/-) B cells in culture with TLR7 and TLR9 ligands resulted in low levels of germ-
line transcripts (GLTs) of γ2a (116). The reconstitution of IRF5-/- B cells by 
retrovirus-delivered IRF5 increased γ2a GLTs, supporting a IRF5-specific and B 
cell-intrinsic role of IRF5 in mediating IgG2a expression (116).  
Therefore, we tested antiviral IgG2a responses in PyV-infected IRF5-/- 
mice. At 4 weeks post PyV infection, IRF5-/- and MyD88-/- mice had low levels of 
VP1 specific IgG2a when compared to WT mice. (Figure 3.3a) However, IRF5-/- 
and MyD88-/- mice generated VP1-specific IgG1 similar to WT mice. (Figure 
3.3b)  To further test whether B cell-intrinsic IRF5 is required for mediating IgG2a 
responses, an in vivo adoptive transfer experiment was performed. RAG1/2 KO 
mice, which lack B and T cells were reconstituted with MACS-purified B cells  
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Figure 3.3- Low levels of VP1-specific IgG2a in IRF5-/- mice 
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Figure 3.3- Low levels of VP1-specific IgG2a in IRF5-/- mice 
 
IRF5-/-, MyD88-/-, and WTB6 infected with PyV were bled 4 weeks post infection 
to determine virus-specific isotype-switched antibody responses. VP1- specific 
(a) IgG2a and (b) IgG1 levels determined from the sera of these mice. Mean +/- 
SD is shown. ***p value < .001 
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from either WTB6 or IRF5-/- mice and with purified WT T cells. After the transfer 
of cells, the two groups of RAG1/2 KO mice, which differed in the expression of 
IRF5 only in their B cell populations, were infected with PyV. VP1-specific total 
IgG levels were lower in RAG1/2 KO mice reconstituted with IRF5-/- B cells than 
with WT B cells 3 weeks post infection. (Figure 3.4a) Moreover, staining for 
IgG2a+ B220+ B cells 6 weeks post infection revealed that RAG1/2 KO mice with 
IRF5-/- B cells generated lower frequencies of IgG2a+ B cells in the spleen 
compared to RAG KO mice with WT B cells. (Figure 3.4b)  
 To test a role for IRF5 in DCs for CSR to IgG2a in response to PyV 
infection, we tested antiviral antibody responses in IRF5 floxed CD11c-Cre mice 
that are deficient for IRF5 only in CD11c+ cells (referred to as CD11c-IRF5-/- 
mice). Exon 2 and exon 3 of IRF5 is floxed out in CD11c-IRF5-/- mice (116). 
CD11c-IRF5-/- mice showed no significant defects in VP1-specific IgG2a 
responses at 3 weeks post infection. (Figure 3.5a) To confirm the cell type-
specific IRF5 defect in the mice used in these studies, CD11c+ cells were MACS-
enriched from spleens of CD11c-IRF5-/- and WTB6 mice to determine IRF5 
transcript levels. Following enrichment of cells, CD11c-positive and CD11c-
negative cell populations, along with whole splenocytes from IRF5-deficient mice, 
were stimulated with IFNβ overnight. Quantitative-PCR determined levels of IRF5 
transcripts in the various cell populations. (Figure 3.5b) Thus, this study 
confirmed that IRF5 was conditionally absent from CD11c+ cells such as DCs. 
CD11c-IRF5-/- mice were able to generate PyV-specific IgG2a at similar levels  
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Figure 3.4- B cell-intrinsic role of IRF5 in mediating IgG2a responses to PyV 
infection 
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Figure 3.4 (cont.)- B cell-intrinsic role of IRF5 in mediating IgG2a responses to 
PyV infection 
 
 
b.  IgG2a+ B cells in RAG KO mice at 6 weeks post PyV infection                                     
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Figure 3.4- B cell-intrinsic role of IRF5 in mediating IgG2a responses to PyV 
infection 
 
RAG1/2 KO mice were reconstituted with MACS-purified B cells from either 
WTB6 or IRF5-/- mice and WT T cells. After the reconstitution of cells, RAG1/2 
KO mice were infected with PyV. (a) 3 weeks post infection, VP1- specific ELISA 
was performed to detect total IgG levels in the sera of RAG1/2 KO mice.  (b) 6 
weeks post infection, splenocytes from reconstituted RAG1/2 KO mice were 
examined for IgG2a+ B cells. IgG2a+ cells were gated on B220+ B cells. 
Mean +/- SD is shown for part a. 
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Figure 3.5-VP1-specific IgG2a responses are not affected in CD11c-IRF5 
conditional knockout mice 
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Figure 3.5-VP1-specific IgG2a responses are not affected in CD11c-IRF5 
conditional knockout mice 
 
b. 
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Figure 3.5- VP1-specific IgG2a responses are not affected in CD11c-IRF5 
conditional knockout mice 
 
Cd11c-IRF5-/- and WTB6 mice infected with PyV were bled at various time 
points post infection. (a) VP1- specific IgG2a responses at 3 weeks post 
infection. (b) Spleen cells were MACS-enriched for CD11c positive and negative 
cells from CD11c-IRF5-/- and WT mice.  Following enrichment, cells were 
stimulated overnight with IFNβ and analyzed by q-PCR for IRF5 transcripts. 
Samples were normalized to b-actin and WTB6 CD11c-positive cells were set at 
the control group. IRF5-/- mice were used as a negative control. β-actin was 
used as the housekeeping control gene in this assay. The data are expressed as 
fold change relative to WTB6 levels of IRF5. 
Control group: CD11c+ cells from WTB6 mice, WT IRF5 expression; Group 1: 
CD11c+ cells from CD11c-IRF5-/- mice; Group 2: CD11c negative cells from 
CD11c-IRF5-/- mice; Group 3: CD11c negative cells from WTB6 mice; Group 4: 
Whole splenocytes from complete IRF5-/- mice. 
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as WT mice which is consistent with a B cell-intrinsic role of IRF5 in mediating 
IgG2a responses to PyV infection.  
In collaboration with Paula Pitha, we have shown that IRF5 mediates the 
induction of IgG2a by regulating the expression of the transcription factor Ikaros. 
The Ikaros family of transcription factors is important in the development and 
maturation of both lymphocytes and non-lymphoid cells. Ikaros has been shown 
to play a role in B cell selection and differentiation (117). Ikaros is also involved 
with allelic exclusion at the Igk locus (118, 119). Ikaros can function as both a 
transcriptional activator and repressor (117). Ikaros knockout mice are not 
viable(120). Studies by Fang et al utilized mice that contain a hypomorphic 
mutation (disrupts gene at a lesser degree) in Ikaros (IkarosL/L), which reduces 
Ikaros expression to ~10% of normal levels (117). IkarosL/L mice display high 
serum levels of IgG2a and IgG2b and lower IgG1 responses (119).  
 IRF5-/- B cells stimulated with TLR ligands or cytokines induced higher 
levels of Ikzf1 (the gene that encodes for Ikaros protein) transcripts and protein 
levels than WT stimulated B cells (116). Retrovirus delivered IRF5 
downregulated ikzf1 transcripts and restored γ2a GLTs, suggesting that IRF5 can 
negatively regulate Ikzf1 expression and that Ikaros expression down-regulates 
IgG2a production (116). IRF5 was also shown to bind upstream of the 
transcriptional start site to an IRF binding site located in the Ikzf1 promoter region 
(116). Through transient transfection assays, IRF5 was observed to stimulate 
Ikzf1 promoter transcriptional activity (116). All of these studies provide evidence 
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that IRF5 negatively regulates Ikaros expression and also enhances IgG2a 
production. Together these studies describe a B cell-intrinsic mechanism for 
IRF5 in regulating IgG2a responses. 
 
D. The role of TLRs in sustaining long-term antibody responses to PyV 
infection  
I utilized 3d mice to study the role of endosomal TLRs in long-term TD 
antibody responses to PyV infection. I infected 3d mice along with WT and 
MyD88-/- mice with PyV. 3d mice behave much like MyD88-/- mice in regards to 
long-term virus-specific IgG responses and the number of long-lived plasma cells 
in the bone marrow in response to PyV infection. Upon PyV infection, 3d mice 
generated low-levels of VP1- specific IgG like MyD88-/- mice starting 2 weeks 
post infection, and the defect was maintained until the latest time point tested, 7 
weeks post infection. (Figure 3.6a-b) At 8 weeks post infection, approximately a 
10-fold decrease in the number of VP1-specific ASCs was observed in the bone 
marrow of 3d mice compared to ASCs in the bone marrow of WT mice. (Figure 
3.6c) There were no significant differences in splenic ASCs between 3d and WT 
mice. The defect in long-lived PC in the bone marrow in 3d mice is similar to the 
defect in long-lived PCs observed in MyD88-/- mice. (Figure 3.6c) Studies with 
3d mice suggest a role for TLR7-and TLR9-MyD88 mediated pathways in 
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Figure 3.6- Defective long-term humoral responses to PyV infection in 3d mice 
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Figure 3.6 (cont.)- Defective long-term humoral responses to PyV infection in 3d 
mice 
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Figure 3.6- Defective long-term humoral responses to PyV infection in 3d 
mice 
 
 (a-b) Long-term VP1-specific IgG in 3d (n=5) mice, MyD88-/- (n=4), and WT 
(n=3) mice from 2 to 7 weeks post infection detected by ELISA. Mean +/- SD is 
shown. (c) ELISPOT assay to detect VP1-specific ASC in the spleen and bone 
marrow of 3d, MyD88-/- and WT mice at 8 weeks post infection (same mice from 
part a). *p value <.05, **p value <.01, ***p value < .001 
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 sustaining long-term B cell responses to PyV infection. The TLR3-TRIF signaling 
pathway may also play a MyD88-independent role in mediating long-term 
humoral immunity to PyV infection. Therefore, it was important to investigate the 
role of individual TLR3, 7, and 9 in this model. Initial studies were conducted with 
TLR9 deficient mice because it recognizes CpG DNA and PyV is a DNA virus.  
Upon infection with PyV, TLR9-/- mice had comparable long-term antibody 
production to WT mice as seen in Figure 3.7a, which shows total PyV-specific 
IgG levels at 8 weeks post infection, the latest time point tested. Furthermore, 
similar numbers of PyV-specific ASCs in the spleen and bone marrow of TLR9-/- 
mice and WT mice were observed at 1.2 years post PyV infection. (Figure 3.7b) 
These data suggest that there were no defects in long-lived plasma cells as 
previously observed in MyD88-/- and 3d mice. It is probable that other TLRs are 
compensating for the loss of TLR9 in TLR9-/- mice. However, these studies 
suggest that TLR9 alone is not required for maintaining long-term antibody 
responses. 
 TLR7 was the next individual TLR to examine. TLR7 is known to 
recognize ssRNA and can signal through MyD88 and activate IRF5. When TLR7-
/- mice were infected with PyV, we observed mild defects in B cell responses. 
One experiment showed that TLR7-/- mice had significantly lower levels of VP1-
specific IgG compared to WT mice at 3 and 5 weeks post infection. (Figure 3.8a) 
However, the difference in virus-specific IgG was not seen at 7 weeks post 
infection. (Figure 3.8a) In the same experiment where defects in antibody levels  
76
Figure 3.7- TLR9 deficient mice generate similar long-term VP1-specific humoral 
responses to WT mice 
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Figure 3.7- TLR9 deficient mice generate similar long-term VP1-specific 
humoral responses to WT mice 
 
(a) Long-term PyV-specific IgG in TLR9-/- (n=4) and WT (n=2) mice 8 weeks 
post infection. (b) Splenic and bone marrow ASCs in TLR9-/- mice 1.2 years post 
infection. Mean +/- SD is shown 
78
Figure 3.8- Mild defects in long-term humoral responses to PyV infection in 
TLR7-/- mice 
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Figure 3.8- Mild defects in long-term humoral responses to PyV infection in 
TLR7-/- mice 
 
(a) VP1-specific IgG levels in TLR7-/- (n=4) and WT (n=5) 1 to 7 weeks post 
infection. (b) VP1-specific ASC in the bone marrow 8 weeks post infection. Mean 
+/- SD is shown. *p value <.05, **p value <.01 
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were observed early after infection, TLR7-/- mice showed lower numbers (not 
significant) of virus-specific long-lived plasma cells in the bone marrow when 
compared to WT mice. (Figure 3.8b) Long-term B cell responses in TLR7-/- were 
inconsistent since TLR7-/- mice showed significant defects only in one 
experiment. The next three experiments with TLR7-/- mice displayed no 
significant differences between TLR7-/- and WT mice in B cell responses upon 
PyV infection. TLR7-/- mice had slightly diminished long-term PyV-specific IgG 
(figure 3.9a) at 4 weeks post infection, but this difference was not significant. 
Similarly, a small and not significant decrease was seen in the generation of 
long-lived plasma cells in the bone marrow at 8 weeks post infection in TLR7-/- 
mice. (Figure 3.9 b-c) TLR3-/- mice had normal levels of long-term VP1-specific 
IgG (shown at 4 weeks post infection). (Figure 3.9a) Individual TLR3-/- and 
TLR7-/- mice generated similar numbers of long-lived PCs to WT mice, unlike in 
MyD88-/- and 3d mice. (Figure 3.9 b-c) These studies with TLR3-/- mice suggest 
that TLR3-TRIFF signaling pathway is dispensable for long-term B cell 
maintenance against PyV infection. These data also suggest that TLR7 and 
TLR9, by themselves, may have a redundant role in anti-PyV B cell responses. It 
is also possible that TLR7 and TLR9 are compensating for each other in single 
TLR7-/- and TLR9-/- mice, since that has been shown to occur in other models 
(121). Since single TLR7-/- and TLR9-/- mice appear to have redundant roles 
and do not have defects in long-term anti-PyV B cell responses, it was important 
to determine the role of both TLR7 and TLR9 in long-term B cell responses to 
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Figure 3.9- Individual TLR3 and TLR7 deficient mice do not display low levels of 
long-term VP1-specific IgG or lower numbers of long-lived PC as 3d or MyD88-/- 
mice 
 
 
a. 
4 weeks post PyV infection 
WT
B6
My
D8
8-/
- 3d
TL
R7
-/-
TL
R3
-/-
My
D8
8/T
RI
F D
KO
0
50000
100000
150000
Ig
G
 T
ite
rs
****
****
>*
  
b. 
 
BM ASC 7 weeks post PyV
My
D8
8-/
-
My
D8
8-T
RI
F D
KO
WT
B6
0
10
20
30
A
SC
/ 1
0^
6
**
 
82
Figure 3.9 (cont.)- Individual TLR3 and TLR7 deficient mice do not display low 
levels of long-term VP1-specific IgG or lower numbers of long-lived PC as 3d or 
MyD88-/- mice 
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Figure 3.9- Individual TLR3 and TLR7 deficient mice do not display low 
levels of long-term VP1-specific IgG or lower numbers of long-lived PC as 
3d or MyD88-/- mice 
 
(a) VP1-specific IgG in 3d, MyD88-/-, individual TLR3-/-, TLR7-/-, and WTB6  
mice at 4 weeks post infection. (b) ASCs in the bone marrow of MyD88-/-, 
MyD88/TRIF DKO and WTB6 mice at 7 weeks post PyV infection. (same mice 
from part a)  (c) ASCs in the bone marrow of TLR7-/- , TLR3-/-, 3d and WTB6 
mice 7 weeks post infection. (same mice from part a) Mean +/- SD is shown.  
>* The IgG2a or IgG1 titers are equal or greater than 128000. **p value <.01, 
****p value < .0001 
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 PyV infection. TLR7/9 DKO mice infected with PyV generated low-levels of VP1-
specific total IgG 3 weeks post infection (Figure 3.10), as seen in MyD88-/- and 
3d mice. These data support a redundant role of TLR7 and TLR9 in generating 
long-term IgG production in response to PyV infection.  
 Viral proteins can activate some surface, non-endosomal TLRs, such as 
TLR2 and TLR4 (16).There has been a report that TLR2 and TLR4 on APCs 
mediate cytokine production upon PyV infection (122). The different Th1 or Th2 
cytokine responses to PyV infection result in PyV-induced tumor resistance or 
susceptibility, respectively (122). This suggests that surface TLR2 and TLR4 can 
be important in the context of PyV-induced tumor formation and in PyV 
recognition. Thus, it was important to investigate the role of TLR2 and TLR4 in 
mediating antibody responses to PyV infection. Studies using single TLR2-
deficient (TLR2-/-) and TLR4-deficient (TLR4-/-) mice did not show defects in 
long-term VP1-specific IgG production (Figure 3.11a) or in long-lived PC in the 
bone marrow. (Figure 3.11b) These data suggest that neither TLR2 nor TLR4 
signaling pathways influence long-lasting antibody responses to PyV infection. 
It is important to remember that these innate signaling pathways are 
complex and redundant. No single TLR knockout mice showed the severely 
defective antibody responses that were observed in MyD88-/- mice and the 3d 
mice. All the data taken together suggest that TLR7 and TLR9 play an important, 
redundant role in maintaining long-term anti-PyV B cell responses.  
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Figure 3.10- Defective long-term PyV-specific IgG levels in TLR7/9 DKO mice 
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Figure 3.10- Defective long-term PyV-specific IgG levels in TLR7/9 DKO 
mice  
 
VP1-specific IgG levels detected in the sera of WTB6 (n=5) and TLR7/9 
DKO (n=5) mice 3 weeks post infection. Mean +/- SD is shown.  ***p value < .001 
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Figure 3.11- TLR2-/- and TLR4-/- mice generate long-term B cell responses to 
PyV infection similar to WT mice 
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Figure 3.11- TLR2-/- and TLR4-/- mice generate long-term B cell responses 
to PyV infection similar to WT mice 
 
VP1- specific ELISA in TLR2-/- (n=5) and TLR4-/- (n=4) and WT (n=5) mice. (a) 
VP1-specific IgG at 5 weeks post infection. (b) Bone marrow ASC in TLR2-/-, 
TLR4-/- and WTB6 mice 8 weeks post infection. Mean +/- SD is shown 
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E. The role of IRF5 in maintaining long-term antibody responses to PyV 
infection 
Since I have shown that TLR7 and TLR9 are important in long-term 
antibody responses to PyV infection and that TLR7 and TLR9 pathways activate  
IRF5, I investigated IRF5 in long-term antibody responses to PyV infection. IRF5-
/- mice generate lower levels of virus specific total IgG than WT mice in response 
to PyV infection. (Figure 3.12a) The defect in PyV-specific IgG in IRF5-/- mice is 
similar to the defective long-term PyV-specific IgG responses observed in 
MyD88-/- mice. (Figure 3.12a) Testing the generation of long-lived plasma cells, 
we found that the IRF5-/- mice developed very low numbers,  
1-3/106 ASCs, in the bone marrow, compared to WT mice (~20/106 ASCs) 8 
weeks post infection. (Figure 3.12b) MyD88-/- mice also showed similar defects 
in BM ASCs as IRF5-/- mice at 9 weeks post infection. (Figure 3.12c) These 
studies suggest that the TLR-MyD88-IRF5-mediated pathway is important in 
maintaining long-term antibody responses to PyV infection. However, it is not 
clear if the TLR-MyD88-IRF5 pathway plays a direct role in B cells to mediate 
long-term anti-PyV B cell responses. 
To study the role of IRF5 within CD11c populations (DCs) in maintaining 
long-term PyV-specific humoral responses, I infected CD11c-IRF5-/- mice with 
PyV. Studies in CD11c-IRF5-deficient mice show no significant differences in 
VP1-specific IgG or in the generation of long-lived PC in the bone marrow. 
(Figure 3.13a-b) These data suggest that the absence of IRF5 in CD11c+ cells 
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Figure 3.12- Defective VP1-specifc long-term IgG and fewer long-lived plasma 
cells in IRF5-/- mice 
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Figure 3.12(cont.)- Defective VP1-specifc long-term IgG and fewer long-lived 
plasma cells in IRF5-/- mice 
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Figure 3.12- Defective VP1-specifc long-term IgG and fewer long-lived 
plasma cells in IRF5-/- mice 
 
VP1- specific IgG responses were measured at various time points post infection 
in IRF5-/-, MyD88-/- and WTB6 mice. (a) PyV-specific IgG at the latest time point 
tested, 8 weeks post infection. (b-c) Splenic and bone marrow ASC were 
determined by VP1- specific ELISPOT in IRF5-/- mice at 8 weeks post infection 
and MyD88-/- mice at 9 weeks post infection. Mean +/- SD is shown. *p value 
<.05, **p value <.01, ****p value < .0001 
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Figure 3.13- CD11c-IRF5-deficient mice generate long-term B cell responses to 
PyV infection similar to WT mice 
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Figure 3.13- CD11c-IRF5-deficient mice generate long-term B cell 
responses to PyV infection similar to WT mice 
 
(a) VP1-specific IgG ELISA on CD11c-IRF5-/- and WTB6 mice 5 weeks post 
infection. (b) VP1-specifc ASC in the bone marrow 7 weeks post infection. Mean 
+/- SD is shown 
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such as DCs may not play an important role in maintaining long-term B cell 
responses. It is important to mention that it was recently discovered that IRF5-/- 
mice, which are widely used in the field, also contain a spontaneous mutation in 
Dock2 (dedicator of cytokinesis 2). Dock2 is a guanine nucleotide exchange 
factor (GEF) involved in regulating Rac signaling pathways and marginal zone B 
cell-development (123). Rac signaling pathways are important in cell migration 
and adhesion (124). This means that the defects observed in IRF5-/- mice could 
be due to the absence of IRF5, or to the lack of Dock2. Of note, CD11c-cre-IRF5-
floxed mice, used here, do not contain a mutation in Dock2 (116). The Dock2 
mutation and its effect on the responses seen in IRF5-/- mice in response to PyV 
are further explained within the discussion section. The next few sections will 
discuss how the lack of MyD88-mediated pathways affects the maintenance of 
long-term antibody responses to PyV infection.  
 
F. GC responses in MyD88-/- mice to PyV infection  
Long-lived plasma cells and memory B cells are derived from GC (GC) B cells.. 
These long-lived populations are required to maintain long-term antibody 
responses. GC responses were examined in MyD88-/- and WT mice upon PyV 
infection. Eight days post infection, I stained for molecules highly expressed by 
GC B cells such as, GL-7, Fas and Bcl-6. Bcl-6 is an important transcription 
factor that is required for the generation of GC B cells. MyD88-/- mice can 
generate similar frequencies of GC B cells in the spleen as WT mice on day 8 
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post PyV infection, as previously observed in our lab (3), and data that I have 
repeated. (Figure 3.14a-b) Previously, our lab has also observed similar levels of 
AID enzyme expression in GC B cells of both WT and MyD88-/- mice (3). The 
GC B cells from WT mice up-regulate Bcl-6 at 40-60%. (Figure 3.14c) The GC B 
cells from MyD88-/- mice also up-regulate Bcl-6 to similar levels as WT mice. 
(Figure 3.14d) This suggests that GC B cells can form normally in MyD88-/- mice 
at early time points post infection. Furthermore, these data support the concept 
that MyD88-mediated signals are not required for initial GC responses during an 
acute PyV infection.  
 In acute viral infections or during protein immunizations the GC response 
usually peaks around 8-10 days post infection/immunization (22, 24). However, 
PyV causes a persistent viral infection and it is never cleared from the host. 
Perhaps the difference in the longevity of IgG responses in WT and MyD88-/- 
mice is due to short-lived GC responses in the MyD88-/- mice. Therefore, we 
investigated the longevity of the GC responses in MyD88-/- mice. GC B cells 
were stained, as described above, in MyD88-/- and WT mice 14 and 21 days 
post infection. MyD88-/- mice generated similar numbers of GC B cells as WT 
mice at day 14-post infection. (Figure 3.15a), but MyD88-/- mice generated lower 
numbers of GC B cells when compared to WT mice at day 21- post infection. At 
21 days post infection, WT mice generated ~1x106 GC B cells/ spleen, whereas 
MyD88-/- mice had less than ~5x105 of GC B cells. (Figure 3.15b) GC B cell 
numbers were also analyzed at 7 months post  
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Figure 3.14- Normal formation of GC B cells in WT and MyD88-/- mice  
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Figure 3.14- Normal formation of GC B cells in WT and MyD88-/- mice 
 
b. MyD88-/- 
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Figure 3.14- Normal formation of GC B cells in WT and MyD88-/- mice 
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Figure 3.14- Normal formation of GC B cells in WT and MyD88-/- mice 
 
 
d. Bcl-6 expression on GC B cells in MyD88-/- mice 
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Figure 3.14- Normal formation of GC B cells in WT and MyD88-/- mice 
 
GL-7hiFashi GC B cells gated on CD19+B220+ B cells in WT (a) and MyD88-/- 
mice (b) 8 days post PyV infection. Bcl-6 expression was detected in WT (c) and 
MyD88-/- mice (d) in the GL-7hiFashi GC B cells described in parts a and b. 
Darker, bold lines represent Bcl-6 expression. Lighter, dashed lines represent 
isotype control. 
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Figure 3.15- A decrease in the number of GC B cells in PyV-infected MyD88-/- 
mice overtime 
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Figure 3.15- A decrease in the number of GC B cells in PyV-infected MyD88-/- 
mice overtime  
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Figure 3.15- A decrease in the number of GC B cells in PyV-infected 
 MyD88-/- mice overtime  
 
Number of GL-7hiFashi GC B cells gated on CD19+B220+ B cells in PyV-infected 
MyD88-/- (n=3) and WT (n=3) mice (a) 14 days, (b) 21 days: **p value <.01, and 
(c) 7 months post infection. Mean +/- SD is shown 
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PyV infection to examine how long GC responses are maintained in this 
persistent virus model. At this late time point, the number of GC B cells was 
lower than the number of GC B cells at 21 and 7 days post infection in WT mice, 
but still above the naïve WT levels. WT mice, 7 months post infection, generated 
~2.5x105 GC B cells. MyD88-/- mice generated ~ <100,000 GC B cells at this 
time point. (Figure 3.15c) Thus, overall, the phenotype that is being observed in 
MyD88-/- mice is that these mice can form GC B cells as well as WT mice 
initially, but overtime, MyD88-deficient mice are not able to maintain GC B cells in 
response to persistent PyV infection. The poor maintenance of the GC response 
may contribute to defects seen in long-term B cell populations in MyD88-/- mice 
to PyV infection. 
 
G. TFH cells in MyD88-deficient mice in response to PyV infection 
There are several molecules and cell types that are important in maintaining GC 
B cells. The defect in GC B cells in MyD88-/- mice is similar to defects observed 
in SAP-deficient animals (52). SAP is one of the several markers that define a 
subset of CD4 T cells known as TFH cells (21). TFH cells are also defined by 
their expression of CXCR5, ICOS, PD-1, SAP, Bcl-6, and several other 
molecules (46). TFH cells are specialized in helping B cells differentiate into GC 
B cells, and they are important in maintaining the GC response within the B cell 
follicle (21). Since we found that MyD88-/- mice are unable to maintain GC B cell 
numbers in response to persistent PyV infection, we examined whether this is 
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due to defects in TFH cells in our system. MyD88-/- mice and WT mice were 
infected with PyV and at 7 and 21 days post infection splenocytes were stained 
for the TFH cell markers CXCR5, ICOS, PD-1, GL-7 and Bcl-6. At 7 days post 
infection, MyD88-/- mice generated similar numbers (~300,000) of TFH cells 
(defined as CD4+T cells positive for CXCR5, PD-1, ICOS and Bcl-6) as WT mice. 
(Figure 3.16a) This is consistent with the fact that normal GC B cell responses 
are observed at this time point.  However, at day 21-post infection, the MyD88-/- 
mice had lower numbers of TFH cells than WT mice. (Figure 3.16b) Similar 
defects in the number of TFH cells at 21 days post infection were observed in 3d 
mice. (Figure 3.17) To further validate the defects in TFH cell numbers, WT and 
MyD88-/- mice were stained with antibodies to PSGL-1 and Ly6C (53). Cells that 
are double negative for PSGL-1 and Ly6C have been shown to greatly express 
TFH cell markers such as CXCR5, PD-1 and ICOS (53). MyD88-/- mice, 
compared to WT mice at 21 days post PyV infection, expressed lower numbers 
of TFH cells which were defined by PSGL-1lo and Ly6Clo cells that were positive 
for CD4, CXCR5, PD-1, and Bcl-6  (Figure 3.16c), supporting data in figures 
3.18b and 3.19. 
 Recent studies have shown a role for regulatory TFH cells (TFR cells) in 
controlling the GC response by directly controlling the number of TFH cells 
present and in the selection of high affinity, antigen-specific 
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Figure 3.16- Number of TFH cells reduced in MyD88-/-mice 21 days following 
PyV infection 
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Figure 3.16 (cont.)- Number of TFH cells reduced in MyD88-/-mice 21 days 
following PyV infection 
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Figure 3.16- Number of TFH cells reduced in MyD88-/-mice 21 days 
following PyV infection 
 
CD4+ T cells positive for CXCR5, ICOS, PD-1 and Bcl-6 were defined as TFH 
cells in (a) PyV-infected MyD88-/- (n=3) and WT (n=3) mice at 7 days post 
infection. (b) In MyD88-/- (n=4), and WT (n=3) mice at 21 days post PyV 
infection. (c) TFH cells defined as CXCR5+ICOS+Bcl-6+ CD4+ T cells that are 
double negative for PSGL-1 and Ly6C were shown in MyD88-/-  (n=2), and WT 
mice (n=3) at 21 days post infection. Mean +/- SD is shown 
**p value <.01, ***p value < .001
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Figure 3.17- Number of TFH cells reduced in MyD88-/- and 3d mice at day 21 
following PyV infection  
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Figure 3.17- Number of TFH cells reduced in MyD88-/- and 3d mice at day 
21 following PyV infection  
  
TFH cell numbers in WT (n=5), MyD88-/- (n=5), and 3d mice (n=4) 21 days post 
PyV infection. TFH cells were determined as CD4+ T cells that were also positive 
for CXCR5, Bcl-6 and PD-1. Mean +/- SD is shown. **p value <.01
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 GC B cell clones. (125) TFR cells express molecules that define TFH cells and 
regulatory T cells such as CXCR5 and FoxP3 respectively. TFR and TFH cells 
also require similar signals for their formation such as SAP and interactions with 
B cells (125). In order to determine whether TFR cells played a role in controlling 
the number of TFH cells generated in MyD88-/- and 3d mice, I stained for TFR 
cells in our system. TFR cells were determined as CD4+CXCR5+PD-1+FoxP3+ 
cells. At seven days post infection, there were slightly lower numbers of TFR 
cells present in MyD88-/- mice, but by day 21, TFR cell numbers in MyD88-/- 
mice were similar to WT levels. (Figure 3.18a-b) 3d mice also did not display a 
defect in TFR cell numbers at 21 days post infection. (Figure 3.18b) These data 
suggest that TFR cells do not influence defects in the maintenance of TFH cells 
in MyD88-/- mice upon PyV infection. 
CXCR5 is a chemokine receptor that is crucial for TFH cells. CXCR5 helps 
in trafficking and locating CD4 T cells within the B cell follicle, where they can 
provide proper help to B cells. CXCR5 expression was examined on CD4 T cells 
in WT and MyD88-/- mice upon PyV infection. WT mice up-regulated CXCR5 to 
9-13%, and MyD88-/- mice up-regulated CXCR5 to 4-8% 7-8 days post PyV 
infection. (Figure 3.19a) The difference in CXCR5 expression on CD4 T cells 
between MyD88-/- and WT mice was significantly greater on day 21-post PyV 
infection. (Figure 3.19a) One experiment also showed similar defects in CXCR5 
expression in 3d mice. (Figure 3.19b) Lower expression of  
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Figure 3.18- No significant differences in the number of regulatory TFH cells in 
MyD88-/-, 3d and WTB6 mice post PyV infection 
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Figure 3.18- No significant differences in the number of regulatory TFH 
cells in MyD88-/-, 3d and WTB6 mice post PyV infection 
 
CD4+ T cells positive for CD4, CXCR5, PD-1 and FoxP3 were defined as TFR 
cells at (a) 8 days post infection in MyD88-/- and WTB6 mice and (b) at 21 days 
post infection in MyD88-/-, 3d and WT B6 mice. Mean +/- SD is shown 
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Figure 3.19- Lower CXCR5+ CD4+ T cells in MyD88-/- and 3d mice post PyV 
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Figure 3.19- Lower CXCR5+ CD4+ T cells in MyD88-/- and 3d mice post PyV 
 
CD4+ T cells from MyD88-/-, 3d and WT mice were analyzed for CXCR5 
expression in separate experiments. (a) Frequency of CXCR5+ CD4+ T cells in 
MyD88-/- and WT mice at 7 and 21 days post infection. (b) Frequency of 
CXCR5+ CD4+ T cells in 3d mice, along with MyD88-/- and WT mice at 21 days 
post infection. Mean +/- SD is shown. *p value <.05, **p value <.01, ***p value < 
.001, ****p <.0001 
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CXCR5 at 7-8 days post infection may influence the number of CXCR5+CD4 T 
cells within the follicle, which can lead to lower numbers of CD4+ T cells 
differentiating into TFH cells and, subsequently, provide less B cell help. This 
potential defect in TFH cells may contribute to the reduction in GC B cell 
responses, which ultimately affects the long-term antibody response. 
In addition to CXCR5, TFH cells express several different molecules such 
as ICOS and PD-1. ICOS and PD-1 signaling have been shown to be important 
not only in the formation of TFH cells, but also in preserving long-lived plasma 
cells (54, 126). The frequencies of ICOS and PD-1 on CXCR5+ CD4 T cells were 
equivalent in WT, MyD88-/- and 3d mice. (data not shown) All of these data 
suggest that not only defects in B cells, but also potential defects in T cell help 
could affect the GC response and ultimately the long-term antibody response in 
MyD88-/- mice upon PyV infection. Thus, it is difficult to determine whether the 
long-term antibody defects in response to PyV infection in MyD88-/- mice are 
completely B cell-intrinsic. 
 
H. General Summary 
In this chapter, the role of innate receptors in regulating humoral responses in 
response to PyV infection was examined. The absence of MyD88 resulted in low 
levels of virus-specific IgG, skewed isotype antibody responses, and defects in 
LLPC (3) and Bmem cell responses. 3d mice and IRF5-/- mice displayed similar 
humoral defects as MyD88-/- mice, suggesting that TLR-MyD88-IRF5 signaling 
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pathways are important in generating antiviral IgG2a responses and potentially in 
maintaining long-term anti-PyV responses. 
 The defect in VP1-specific IgG2a responses was shown to be a B cell-
intrinsic defect. Adoptively transferring IRF5-/- B cells or WT B cells with WT T 
cells into RAG KO mice showed that only the presence of IRF5-/- B cells and WT 
T cells resulted in low levels of VP1- specific IgG2a and lower frequencies of 
IgG2a+ cells. Additionally, re-expressing IRF5 in IRF5-/- B cells restored levels of 
y2a transcripts. These studies, in collaboration with Paula Pitha, determined that 
IRF5 mediates IgG2a responses within B cells by mediating the expression of 
Ikaros. 
 3d mice also displayed similar defects in VP1- specific IgG2a as in 
MyD88-/- mice, but generated normal virus-specific IgG1. Studies in individual 
TLR 3,7, and 9 single knockout mice did not reveal a defect in PyV-specific 
IgG2a, suggesting that more than one of these endosomal TLRs have a 
redundant role in mediating this isotype response. TLR7/9 DKO mice showed 
defective VP1-specific IgG2a responses, further suggesting the redundant role of 
TLR7 and TLR9 in regulating PyV-specific IgG2a responses. TLR7 and TLR9 are 
known to signal through MyD88 and IRF5, thus based on the data shown, TLR7 
and TLR9 are likely to be involved in regulating IgG2a responses to PyV.  
 Along with defects in IgG2a production, MyD88-/- mice, 3d mice, and 
IRF5-/- mice are unable to maintain long-term VP1-specific IgG and have low 
numbers of long-lived plasma cells in the bone marrow. Again, TLR 3, 7 and 9 
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single knockout mice did not show similar long-term B cell defects as 3d, MyD88-
/- or IRF5-/- mice. These data with single TLR knockout mice support the idea 
that TLR7 and TLR9 are important in preserving long-term B cell responses to 
PyV. TLR7/9 DKO mice had low-levels of PyV-specific IgG, supporting the 
redundant role of TLR7 and TLR9 to mediate long-term anti-PyV B cell 
responses. It is not clear at the moment how the absence of MyD88 signaling in 
B cells, DCs, and T cells contributes to the defective long-term humoral response 
observed in MyD88-/- mice to PyV infection. 
 Further studies in this chapter showed that the defect in long-term 
antibody responses in MyD88-/- mice correlated with the poor maintenance of 
GC B cells. MyD88-/- mice could generate normal GC B cell numbers during 
acute PyV infection, but MyD88-/- mice could not maintain GC B cells at later 
time points post infection. It was also shown that MyD88-/- mice had lower 
number of TFH cells present, which could affect the GC B cell response and 
ultimately the long-term antibody response. 
This chapter reveals how a persistent antigen maintains GC B cell 
responses longer and the pool of long-lived B cell populations in a MyD88-
dependent manner. More importantly, this chapter provides evidence of how 
innate signaling pathways can help preserve long-term humoral protection to 
persistent virus infection. 
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CHAPTER IV: Role of PyV load and innate signaling pathways in sustaining 
long-term antiviral TI responses 
The long-term maintenance of virus-specific antibodies prevents the 
recrudescence of viral infections and plays an important role in the control of 
persistent infections. Two types of long-lived antigen-specific B cell populations 
maintain sustained serum immunoglobulin levels:  long-lived plasma cells and 
Bmem cells. Both of these long-lived B cell populations are thought to be 
dependent on T cell help, derive from GC responses and produce highly specific, 
class switched antibodies. In contrast, antibody responses generated without T 
cell help, the so called T cell-independent (TI) antibody responses are usually 
short-lived (127). The typical TI antigens, such as bacterial polysaccharides or 
NP (4-Hydroxy-3-nitrophenylacetyl)-Ficoll, are not proteins and thus cannot be 
processed by antigen presenting cells and presented as peptides to activate 
helper CD4 T cells. TI antigens, in general, do not induce GC formation and 
subsequent long-lived plasma cell and Bmem cell generation. 
Persistent viral infections, such as infections with human or murine 
polyomaviruses, require all aspects of the immune system to keep the viral load 
in check for the host’s lifetime. PyV is well controlled and does not cause disease 
in immunocompetent animals, but leads to tumor development after many 
months in completely T cell-deficient mice (2, 95). In addition to inducing efficient 
T cells and T cell-dependent B cell responses in normal hosts, PyV infection can 
induce a potent T cell-independent IgG response in T cell-deficient mice. These 
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TI antibody responses are protective (97), in that they reduce viral load and 
prevent virus-induced lethal acute myeloproliferative disease observed in PyV-
infected T and B cell-deficient SCID mice (88). This suggests that in a partially 
immune compromised T cell-deficient host, TI antibody responses can help 
control the persistent viral infection. Also, transfer of sorted follicular or marginal 
zone B cells into SCID recipients prior to PyV infection resulted in protective TI 
IgM and IgG anti-PyV responses (97). Several other viruses, besides PyV, were 
shown to be also capable of inducing TI antiviral antibody responses. (1) This 
chapter uses PyV-infected mice as a model to further understand the 
mechanisms that are required to generate and maintain protective TI IgG 
responses. 
TCRαβ KO mice (that lack αβ T cells) and TCRβδ/or TCRαβγδ KO mice 
(that lack both αβ and γδ T cells) survive PyV infection for many months, but 
maintain a significantly higher (~10-fold higher) persisting virus load than wild 
type B6 mice (95).  The relatively long life span of T cell-deficient PyV-infected 
mice, which, in terms of adaptive immunity to PyV, have only TI B cell responses, 
suggests that the TI IgG responses may be long-lived, because mice which lack 
both T and B cells die rapidly after infection (88). This chapter provides evidence 
that PyV-infected T cell-deficient mice have long-lasting antiviral serum IgG 
responses, but the longevity of these responses is not due to the presence of 
long-lived bone-marrow residing plasma cells or Bmem cells. Instead, the 
sustained TI IgG is likely to be continuously generated by short-lived B cell 
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responses that require persisting virus and intact MyD88-mediated innate 
immune pathways. 
 
A. Sustained antiviral IgG responses in the sera of PyV-infected T cell-
deficient mice 
To test the longevity of antibody responses in T cell-deficient mice, antiviral 
serum IgG levels of TCRβδ KO mice and control immunocompetent B6 mice 
were measured by VP1-ELISA at various time points post PyV infection. At 3 
months post infection, TCRβδ KO mice maintained VP1-specific IgG levels in the 
serum, similarly to that in B6 wild type mice. (Figure 4.1a)  Pooled serum 
samples taken from TCRβδ KO mice in an independent experiment also showed 
the maintenance of virus-specific IgG responses up until 6 months post infection, 
the latest time point tested.  This was similar to the sustained long-term IgG in 
the pooled sera of B6 mice. (Figure 4.1b) The VP1-specific IgG titers were 
approximately 20 fold higher in B6 mice at 6 months post infection than in TCRβδ 
KO mice (data not shown), and these data on the magnitude of TI IgG responses 
are consistent with many experiments in our laboratory, including our previously 
published findings (4). 
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Figure 4.1- Long-lived serum IgG responses to PyV in T cell-deficient mice 
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Figure 4.1- Long-lived serum IgG responses to PyV in T cell-deficient mice 
 
(a) TCRβδ KO mice (n=5) and wildtype mice (n=2) were examined by ELISA for 
VP1- specific IgG at 3 months post infection. Mean +/- SD is shown. (B) VP1- 
specific IgG in pooled sera of TCRβδ KO mice (n=4) at 1:4000 dilution and of 
WTB6 mice (n=7) at 1:50,000 dilution.  
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B. Lack of GC B cells in T cell-deficient mice 
Long-lived antibody responses in T cell-sufficient hosts usually derive from long-
lived plasma cells or from the activation of Bmem cells, and both of these cell 
types are normally generated from T cell-dependent GC responses. 
Nevertheless, there are reports of short-lived TI GC responses and TI B cell 
memory in the literature (8). Moreover, unlike the conventional TI antigens, which 
are mostly polysaccharides or lipopolysaccharides, the chemical nature of the 
PyV capsid is protein, and PyV as a TI antigen can induce TI IgG2a, an isotype 
not common in responses to other TI antigens. The distinct nature of PyV as a 
TI-2 antigen suggests that TI responses to PyV infection may have features not 
characteristic for conventional TI-2 responses such as GC formation. Studies 
have shown that a TI-2 antigen, (4-hydroxy-3-nitrophenyl)acetyl-Ficoll, can 
generate short-term GCs (8). Therefore, we tested for the possibility that T cell-
deficient mice form GC upon PyV infection. TCRβδ KO mice and wild type 
controls were infected intraperitoneally with PyV. Eight days post infection we 
harvested spleens from these mice and stained for GC B cells. Spleen cells 
gated on CD19+B220+ cells and double positive for GL-7 and Fas were 
considered as GC B cells (25, 26).  The percentage of GC B cells in the spleens 
of wild type B6 mice increased from 0.11% in uninfected mice to 2.05% by day 8. 
(Figure 4.2)  On the other hand, T cell-deficient mice did not have GC B cells in 
the spleen above the frequencies in 
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Figure 4.2- Lack of GC B cells in the spleens of PyV-infected T cell-deficient mice 
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Figure 4.2- Lack of GC B cells in the spleens of PyV-infected T cell-deficient 
mice 
 
Spleens of naïve and day 8 PyV-infected TCRβδ KO and WTB6 mice were 
examined by flow cytometry. The FACS plots are gated on B220+CD19+ B cells; 
the box/gate indicates Fashi GL-7hi GC B cells. 
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 naïve controls (Figure 4.2). These data show that T cell-deficient mice, as 
expected, are not able to generate GC B cells in response to PyV.  
 
C. Lack of bone marrow plasma cells and memory B cells in T cell-deficient 
PyV-infected mice 
Since it was shown that T cell-deficient mice are unable to make GCs but still 
have long-term IgG antibodies in their serum, I investigated if long-term B cell 
populations could maintain the TI B cell response. It has been reported that 
immune responses to TI-2 antigens can involve Bmem cells (5). Since PyV is a 
TI-2 antigen, we wanted to test whether the presence of long-lasting antiviral IgG 
responses in T cell-deficient mice was due to long-lived plasma cells and/or 
Bmem cells. TCRβδ KO mice and wild type controls were infected with PyV and 
at various time points their spleens and bone marrows were tested for VP1-
specific antibody-secreting cells (ASC) by ELISPOT. (Figure 4.3) Wild type B6 
mice, as shown in figure 4.3, had 40-140/106 splenic ASC at all three time points 
after infection, and there was a similar increase in splenic ASCs in T cell-deficient 
mice. The number of virus specific ASCs in the bone marrow gradually increased 
in wild type B6 mice from 3 weeks to 6 months from 10/106 to ~80/106 bone 
marrow ASCs, respectively. On the  
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Figure 4.3- Accumulation of VP1-specific ASC in the bone marrow of B6 but not 
of TCRβδ KO mice after PyV infection 
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Figure 4.3- Accumulation of VP1-specific ASC in the bone marrow of B6 but 
not of TCRβδ KO mice after PyV infection 
 
TCRβδ KO (left) and B6 mice (right) were examined for VP1- specific IgG ASC 
by ELISPOT at 3 weeks, 6 weeks and 3 months post PyV infection. Black bars: 
spleen ASC, open bars: BM ASC. Mean +/- SD is shown.  
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other hand, there was no increase in ASCs in the bone marrow of T cell-deficient 
mice, suggesting that T cell-deficient mice are not able to generate long-lived 
plasma cells in response to PyV infection.  
Bmem cells are the other population of B cells that contribute to long-term 
humoral immunity. In order to study mouse memory B cell responses, we used a 
functional adoptive transfer assay as described in Chapter III. In this functional 
memory B cell assay, SCID mice were reconstituted with either of the following 
groups of splenocytes: naïve or PyV-immune splenocytes from TCRαβ KO mice, 
naïve or PyV-immune splenocytes from TCRγδ KO mice, naïve or PyV-immune 
splenocytes from TCRαβγδ KO mice, and naïve or PyV-immune splenocytes 
from WTB6 mice. Following cell transfer, some mice from each experimental 
group were infected with PyV. SCID mice given virus-immune wild type B6 cells 
or TCRγδ KO cells, followed by a PyV infection, generated good recall (Bmem 
cell) responses to PyV. (Figure 4.4) Alternatively, SCID mice reconstituted with 
virus-immune TCRαβ KO or TCRαβγδ KO splenocytes, followed by a PyV 
challenge did not generate Bmem cell responses, demonstrating that Bmem cell 
recall responses to PyV infection depends on αβ T cells. 
Therefore, these observations taken together provide evidence that the 
long lasting serum antibody responses observed in T cell-deficient mice are not 
due to the presence of long-lived plasma cells or Bmem cells.  
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Figure 4.4- The generation of B cell memory, measured as VP1- specific IgG 
recall response, requires αβ T cell help 
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Figure 4.4- The generation of B cell memory, measured as VP1- specific IgG 
recall response, requires αβ T cell help 
 
 Splenocytes (107) from previously PyV infected (PyV immune) or naive TCRαβ 
KO, TCRγδ KO, TCRαβγδ KO or WT mice were intravenously transferred into 
SCID recipients. One day-post transfer, 2 out of 3 SCID recipients received a 
secondary PyV infection. VP1- specific IgG was determined by ELISA from sera 
of SCID recipients 7 days post infection. 
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D. Persisting viral load is higher in T cell-deficient mice compared to wild 
type  
CD4 T cell-deficient mice (I-Ab-/-) infected with PyV generate only short-term 
antibody responses to PyV and lack long-lived plasma cells in the bone marrow 
(94). Therefore, TI antibody responses are not maintained long-term in mice that 
lack CD4 T cells, but have functional CD8 T cells (94).  This contrasts with mice 
that lack both CD8 and CD4 T cells and maintain persistent TI antiviral serum 
IgG responses. PyV is a persistent virus infection, and CD8 T cells are known to 
be effective in controlling the virus load (89, 90).  We hypothesized that an 
elevated virus load in mice lacking all T cells, including CD8 T cells, compared to 
I-Ab-/-, which lack CD4 T cells but have CD8 T cell responses to PyV, may play a 
role in maintaining long-lived TI antibody responses, and possibly explain the 
profound differences found in the longevity of TI antiviral IgG responses in I-Ab-/- 
and TCRβδ KO mice. PyV levels in the kidney, lung and spleen of TCRβδ KO 
mice and wild type B6 controls were determined on day 14 following  
intraperitoneal or intranasal infection. In both types of infections, the TCRβδ KO 
mice had 10-fold higher levels of PyV than wild type mice (Figure 4.5a-b). Thus, 
in contrast to CD4 T cell-deficient mice, which have persistent PyV in their 
organs at the same levels as wild type B6 mice (94), TCRβδ KO mice have 
higher  
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Figure 4.5- Higher PyV viral load in T cell-deficient mice than in B6 mice  
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Figure 4.5- Higher PyV viral load in T cell-deficient mice than in B6 mice  
 
PyV loads were determined as PyV genome copies/µg of tissue DNA by real time 
q-PCR in (a) kidney, lung and spleen 14 days post infection i.p. of TCRβδ KO 
and WT mice, (b) in lung, kidney, spleen and liver 14 days post i.n. infection of 
TCRβδ KO and WT mice. 
137
levels of PyV, which may contribute to the maintenance of long-lasting TI 
antibody responses in these mice. 
 
E. Decrease in virus load after transfer of CD8 T cells into TCRβδ KO mice 
is associated by rapidly declining antiviral serum IgG levels  
To test whether high levels of persistent PyV are responsible for the long-lasting 
antibody responses in T cell-deficient mice, naïve CD8 T cells, obtained by 
MACS enrichment from spleens of uninfected wild type B6 mice, were 
transferred into TCRβδ KO mice. The following day (day1), the CD8 T cell-
reconstituted TCRβδ KO mice were infected with PyV, similarly to a control group 
of T cell-deficient mice that received no cell transfer. PyV-specific IgG levels in 
 the serum were determined by VP1-specific ELISA at 1, 3, 5 and 7 weeks post 
infection.(Figure 4.6a)  At 1-week post infection, the VP1- specific IgG response 
was similar between the two groups. In spite of this, over time, TCRβδ KO mice 
that had received CD8 T cells generated lower levels of virus-specific IgG. PyV 
viral loads were also measured at the last time point of the study (7 weeks post 
infection) (Figure 4.6b). This experiment established a correlation between the 
presence of CD8 T cells, lower persisting viral loads, and lower antibody 
responses.  
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Figure 4.6- Transfer of CD8 T cells prior to PyV infection reduces serum IgG in T 
cell-deficient mice and decreases lowers PyV load  
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Figure 4.6- Transfer of CD8 T cells prior to PyV infection reduces serum IgG 
in T cell-deficient mice and decreases lowers PyV load  
 
 TCRβδ KO mice (n=5) were injected i.v. with 7x106MACS-purified WT CD8 T 
cells, while another group of TCRβδ KO mice (n=5) were given no cells. 
Following cell transfer, all mice were infected with PyV i.p. (a) At 1,3, 5, and 7 
weeks post infection, virus-specific IgG levels were determined by VP1-specific 
ELISA (b). PyV loads were determined by q-PCR at the latest time point tested; 7 
weeks post infection and were expressed as PyV genome copies/mg tissue 
DNA. 
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F. Lack of long-lasting antiviral IgG responses in T cell-deficient MyD88-
deficient mice 
Based on our finding thus far, we hypothesized that a high level of persistent PyV 
antigen in TCRβδ KO mice may activate naïve B cell populations that emerge 
from the bone marrow continuously, thereby maintaining the long-lasting TI IgG 
response. This envisioned mechanism poses the question of why B cells that are 
 likely to encounter PyV antigens during their development in the bone marrow 
resist becoming tolerized? Bone marrow cells from TCRβδ KO mice 3-4 months 
post infection indeed contained high levels of PyV genomic DNA, as detected by 
qPCR, indicating the presence of high viral load at the site of B cell development 
(Figure 4.7). Therefore it is highly probable that developing B cells encounter 
PyV in the bone marrow, but, this encounter does not seem to lead to tolerance 
because newly emerging mature B cells keep generating antibody after they  
interact with PyV in the periphery. A report by Berland et al. (128) suggested that 
antigens with “dual specificity”, which ligate the BCR and endosomal TLRs such 
as TLR7/8 and TLR9 may break B cell tolerance. In that study, B cells with a 
transgenic B cell receptor specific for autoantigens showed a TLR7-dependent 
loss of B cell tolerance.  If we define “dual specificity antigen” as antigens that 
activate both BCR and TLRs, PyV can be considered as a “dual specificity 
antigen”.  PyV infection, indeed, results in the activation of endosomal MyD88-
mediated TLRs as shown by studies in Unc93B1 mutant mice that cannot signal 
through the endosomal TLRs 3, 7 and 9 (Chapter III). Therefore, we  
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Figure 4.7- High levels of persisting PyV in the bone marrow of T cell-deficient 
mice 
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Figure 4.7- High levels of persisting PyV in the bone marrow of T cell-
deficient mice 
 
 PyV loads were determined as PyV genome copies/µg of tissue DNA by real 
time q-PCR in the bone marrow of TCRβδ KO mice and WT mice 3-4 months 
post infection i.p. 
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hypothesized that B cells in TCRβδ KO mice, with high levels of PyV in the bone 
marrow, bypass tolerance to PyV in a TLR-dependent manner. This disruption of 
tolerance may be also dependent on MyD88, a cytoplasmic signaling protein 
important for the action of many TLRs. Thus, it would follow that in TCRβδ KO 
mice that are also deficient in MyD88 signaling tolerance would be developed 
and maintained; and new B cells coming out from the bone marrow would not  
respond to persisting PyV, leading to decreased antiviral serum IgG with time. To 
test this hypothesis, we infected TCRβδ KO /MyD88-/- triple knockout mice and 
mice that were T cell-deficient but MyD88+/+ (TCRβδ KO) with PyV.  VP1-
specific IgG responses were tested at 1, 2 and 4 weeks post PyV infection. 
(Figure 4.8a) The TCRβδ KO/MyD88-/- mice had similar levels of virus-specific 
IgG as TCRβδ KO mice at 1-week post infection, but, the long-lasting antibody 
response was not maintained in these mice at 2 and 4 weeks post infection. 
TCRβδ KO/MyD88-/- and TCRβδ KO mice generated similar levels of VP1-
specific IgM. (Figure 4.8b) This shows that the absence of MyD88 signaling did 
not just merely block switching to IgG in TCRβδ KO /MyD88-/- mice and further 
supports the tolerance hypothesis. These results suggest that MyD88 signaling is 
essential in maintaining long-lasting antibody responses in T cell-deficient mice 
after virus infection. 
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Figure 4.8- VP1-specific IgG and IgM responses in T cell-deficient MyD88 +/+ 
and T cell-deficient MyD88 -/- mice 
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Figure 4.8- VP1-specific IgG and IgM responses in T cell-deficient MyD88 +/+ 
and T cell-deficient MyD88 -/- mice 
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Figure 4.8- VP1-specific IgG and IgM responses in T cell-deficient MyD88 
+/+ and T cell-deficient MyD88-/- mice 
 
TCRβδ KO MyD88-deficient (n=5) and TCRβδ KO MyD88 sufficient mice (n=5) 
were infected with PyV i.p. (a) VP1- specific IgG was determined by ELISA at 1,2 
and 4 weeks post PyV infection. (b) VP1-specific IgM was determined at 4 weeks 
post PyV infection. >* The IgG titers are equal or greater than 128000. ***p value 
< .001  
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G. General Summary 
This chapter provides evidence that PyV-infected T cell-deficient mice have long-
lasting antiviral serum IgG responses, and the longevity of these responses is not 
due to the presence of long-lived bone marrow-residing plasma cells or Bmem 
cells. Instead, the sustained TI IgG is likely to be continuously generated by  
short-lived B cell responses that require high persisting virus load and intact 
MyD88-mediated innate immune pathways.  
TI IgG responses were maintained up to 6 months post PyV infection in 
the absence of T cells. Even though other TI models have suggested the 
occurrence of ‘TI B cell memory’ by the presence of antigen-experienced, 
quiescent, IgG memory B cells, (5)the long-term TI IgG responses seen in 
TCRβδ KO mice were not a result of GC formation and GC-derived long-lived 
plasma cells or the activation of recall memory B cells. 
 Previously, it has been shown that CD4+ T cell-deficient mice generate 
short-lived antibody responses to PyV and maintain a PyV load that is similar to 
WT mice (94). In this chapter, I have shown that TCRβδ KO mice (which lack 
both CD4 and CD8 T cells) had long-lasting TI IgG responses and higher PyV 
loads than WT mice. This suggests that the virus load plays a role in sustaining 
long-term TI IgG responses. Adoptively transferring WT CD8 T cells into TCRβδ 
KO mice prior to PyV infection resulted in gradually decreasing levels of VP1-
specific IgG, associated with a lower PyV load than TCRβδ KO mice without CD8 
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T cells, again supporting the idea that the high virus load was required for 
sustained TI antibody responses. 
Based on the viral load data, it was hypothesized that that a high level of 
persistent PyV antigen in TCRβδ KO mice may activate naïve B cell populations 
that emerge from the bone marrow continuously, thereby maintaining the long-
lasting TI IgG responses. As high PyV loads were also detected in the bone 
marrow where B cell lymphopoeisis occurs, I questioned if developing B cells 
encounter PyV antigens, why weren’t B cells that enter the periphery, then, 
tolerized? As a dual specificity antigen, it is reasoned that PyV can activate both 
BCR and TLR-signaling pathways. The activation of both of these signaling 
pathways by high levels of an autoantigen has been shown to lead to the 
breaking of tolerance and autoantibody production (128). Using TCRβδ KO mice 
that were also deficient in MyD88 signaling, I showed that overtime these mice 
generated lower levels of PyV-specific IgG. Thus, MyD88-meditated signaling 
can affect the tolerization of B cells which influences long-term TI IgG production 
in response to PyV infection. 
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CHAPTER V: Discussion 
Our lab has previously shown that MyD88-/- mice have defects in long-
term humoral immunity in response to PyV infection. MyD88-/- mice had low 
levels of PyV-specific IgG, skewed isotype responses and a lack of in long-lived 
plasma cells in the bone marrow (3). 
 There has been controversy in the literature over the importance of direct 
TLR signaling on B cells in the maintenance of humoral responses. Pasare et al 
had shown a direct and indirect role of TLRs in B cell responses.  In their studies, 
MyD88-deficient mice immunized with OVA-LPS displayed defects in total IgG, 
lower levels of IgG1, and an abolishment of IgG2a/c OVA-specific responses. 
Studies that depleted regulatory T cells in MyD88-/- mice restored helper T cell 
activation and function. However, the restoration of helper T cell activity did not 
reestablish TD B cell responses in MyD88-/- mice (66). These data suggested 
that direct TLR signaling in B cells might be important for normal TD antibody 
responses.  
 To the contrary, Gavin et al used MyD88-/-;TrifLPS2/LPS2 (deficient in all TLR 
signaling) mice to show that TLR signaling is not important for antibody 
responses to protein antigens delivered with various adjuvants (129). Gavin et al 
suggested the use of LPS as an adjuvant in the studies by Pasare et al 
influenced the outcome of that study. Another study showed that the transfer of 
MyD88-/- B cells into B cell-deficient mice that were subsequently immunized 
with NP-CGG generated similar NP-antibody titers as WT B cells. The addition of 
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LPS enhanced the antibody response to NP-CGG, but no defects in antibody 
responses were observed from MyD88-/- B cells in these studies (130).  
 Nevertheless, several other studies in the literature have corroborated a 
humoral defect in MyD88-/- mice, confirming observations made in our lab. 
MyD88-/- mice infected with murine gamma herpesvirus 68 (MHV68) generated 
low numbers of activated B cells, GC B cells and class-switched B cells 16 days 
post infection (131). To investigate the role of MyD88 in B cells to maintain WT 
antibody responses, WT mice were irradiated and reconstituted with a mixture of 
WT and MyD88-/- bone marrow cells. Chimeric mice with MyD88-/- B cells 
generated similar defective anti-MHV68 humoral responses as MyD88-/- mice 
which confirmed a B cell-intrinsic role of MyD88 in maintaining antibody 
responses and GC reactions (131). Intranasal infection of MyD88-/- mice with 
vesicular stomatitis virus (VSV) infection resulted in impaired IFNα production, 
defective neutralizing antibodies, and low levels of anti-VSV IgG2a (132). 
Additionally, MyD88-/- mice infected by influenza A virus showed lower levels of 
total IgG and defective levels of virus-specific IgG2a 21 days post infection (133). 
MyD88-/- mice challenged i.p. with a non-viral pathogen, heat-killed 
Streptococcus pnuemoniae, also showed defects in IgG3, IgG2b and IgG2a 
(134). In vitro studies have also shown that different B cell subsets can secrete 
various cytokines, antibodies and proliferate in response to TLR ligands, further 
showing a role of TLRs in mediating B cell responses (116, 135). All of these 
studies provide evidence for the role of MyD88-mediated signaling to be 
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important in B cells. The work in Chapter III elucidated the role of innate signaling 
pathways in CSR and in the regulation of long-term antiviral TD humoral 
immunity to PyV infection. 
 Chapter III describes the role of MyD88-mediated signaling in regulating 
IgG2a responses, GC B cell reactions, long-lived plasma cells, and memory B 
cells to PyV infection. Previous studies in our lab have shown that MyD88-/- 
mice, upon PyV infection, generate low-levels of virus-specific IgG, attenuated 
levels of virus-specific IgG2a, and lower numbers of long-lived plasma cells (3). 
The work in this thesis and our collaboration with Dr. Paula Pitha provided a 
mechanism for the TLR-MyD88-activated transcription factor IRF5 in mediating 
IgG2a responses within B cells. My thesis work also determined that TLR7 and 
TLR9 (through studies in 3d mice and TLR7/9 DKO mice) are important in the 
generation and maintenance of long-term antiviral humoral responses. The 
defect in long-term IgG responses and long-lived B cell populations in MyD88-/- 
mice may result from defective innate pathways in multiple cell types, as MyD88 
signaling is important in several cell types, not just B cells. 
 
A. Role of B cell-intrinsic IRF5 in isotype switching to IgG2a 
Chapter III discussed a role for TLR-MyD88-IRF5-mediated mechanism in class 
switching to IgG2a. In addition to IRF5, other molecules have been shown to be 
important in generating IgG2a such as the transcription factor, T-bet, IRF4 and 
AID. T-bet is a transcription factor that is generally induced in B cells upon LPS 
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and CD40 stimulation in vitro and is primarily important in IgG2a induction during 
TI B cell responses rather than TD B cell responses. (136) IFNy secretion by 
non-T cells, such as NK cells, can activate IgG2a production by LPS-activated B 
cells in vitro (137). Also, it has been shown that the induction of IgG2a GLTs in B 
cells requires IFNy-mediated up-regulation of T-bet. (102) Therefore, it was 
important to investigate T-bet expression in IRF5-/- B cells. T-bet levels were not 
affected in IRF5-/- B cells stimulated with TLR ligands, suggesting that the defect 
in IgG2a in IRF5-/- mice is not dependent on T-bet (116). It is of note to mention 
that another study did observe defects in T-bet expression in CpG (TLR9 ligand)-
stimulated IRF5-/- B cells (115). The difference in T-bet expression in these 
studies could be due to the kinetics of T-bet expression. Savitsky et al examined 
T-bet expression 6 hours post CpG stimulation and observed a defect in T-bet 
expression. However, T-bet expression in TLR-stimulated IRF5-/- B cells was not 
affected when observed two days post stimulation (116). T-bet expression is 
delayed upon CpG-stimulated IRF5-/- B cells(116), which can contribute to the 
discrepancy in T-bet expression in the two studies described.  
AID is an important enzyme that is required for CSR, as AID-deficient B 
cells are not able to class switch (19). Studies looking at AID transcripts in TLR-
stimulated IRF5-/- B cells showed that AID was not decreased when compared to 
WT-stimulated B cells (116). This suggests that the defect IgG2a production in 
IRF5-/- B cells is not a result of lower levels of AID. 
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IRF4 plays an essential role in B cell differentiation into plasma cells and 
in CSR (111) (116). Studies show that upon TLR-activation, IRF4 and IRF5 
compete for binding to MyD88 (138). IRF5-/- B cells stimulated with LPS, LPS 
and IL-4 or TLR7 and TLR9 ligands, showed no reduction in the expression of 
IRF4. This supports the idea that the absence of IRF5 does not affect IRF4, and 
IRF4, in turn, is not responsible for the defect in CSR observed in IRF5-deficient 
mice (116).  
IRF5, in its activated form, is known to form homodimers or heterodimers 
with other IRF proteins such as IRF3 and IRF7. IRF5/IRF3 have different function 
than IRF5/IRF7 in regards to type I IFN production (139). Studies in Chapter III 
describe another mechanism of IRF5. IRF5 can negatively regulate Ikaros 
expression by binding to the Ikzf1 promoter region and control transcriptional 
activity (116). In addition to IRF5, IRF4 and IRF8 were shown to be able to bind 
to the IRF binding site in the promoter region of Ikzf1 (116). Other studies have 
shown that IRF4 and IRF8 can stimulate Ikzf1 expression to negatively regulate 
pre-B cell proliferation. (140)Yet, only IRF5 and IRF8 were able to control Ikzf1 
transcriptional activity. (116) This discrepancy may be due to necessity of an 
association of IRF4 with other lymphoid cell-specific transcription factors to 
facilitate transcriptional activity of Ikzf1 (141). 
A recent finding of a spontaneous genomic duplication and a frameshift 
mutation in Dock2 in IRF5-/- mice has complicated the interpretation of 
experiments conducted in IRF5-/ mice (123). Dock2 is involved in regulating Rac 
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signaling pathways, marginal zone B cell-development, plasmacytoid DC 
homing(124) and B cell development. All studies with IRF5-/- mice with PyV 
infection in this thesis were done using IRF5-/- mice that also contained the 
Dock2 mutation. Nevertheless, Fang et al demonstrated that B cells obtained 
from a Dock2 mutation-free, IRF5-deficient mice showed the same IgG2a class 
switching defect as did the IRF5-/- and Dock2 mutation-carrying mice (116). 
Dock2 mutation-free, IRF5-deficient mice were generated by crossing IRF5 
floxed mice with OzcCre-expressing mice. The cre gene, in OzCre mice, is under 
the control of the phosphoglycerate kinase-1 (PGK) promoter. Additionally, a 
spontaneous Dock2 mutation was found in apoptosis-associated specklike 
protein containing a caspase recruitment domain (ASC) KO mice as well. ASC is 
an adaptor protein found downstream of inflammasome receptors. Infection of 
ASC KO mice with PyV did not result in any humoral defects (data not shown) as 
observed in MyD88-/-, 3d-/ or IRF5-/- mice, indicating that Dock2, solely, is not 
responsible for the B cell defects we found in IRF5-/- mice. At this point we can 
conclude that (i) the IgG2a defect is due to IRF5 mutation and not merely caused 
by Dock2 defect, and (ii) mice lacking both IRF5 and Dock2 have long-term 
antibody defects in response to PyV. The individual roles of IRF5 and Dock2 
needs to be sorted out in studies with IRF5-deficient, Dock2 sufficient mice. 
 We also started to conduct studies using IRF5 floxed mice that were 
crossed with CD11c-Cre mice. These mice are selectively deficient in IRF5 in 
CD11c positive populations and do not carry a Dock2 mutation. As described in 
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Chapter III, CD11c-IRF5-deficient mice did not display defects in IgG2a 
production. These studies are consistent with a B cell-intrinsic role of IRF5 in 
mediating IgG2a responses. 
 
B. Role of TLR pathways in mediating anti-PyV igG2a responses  
3d mice have similar defects in virus-specific IgG2a responses as MyD88-/- and 
IRF5-/- mice, which suggests that TLR7- and TLR9-MyD88 mediated pathways 
are important in the PyV infection model. 3d mice are deficient in TLRs 3, 7, and 
9 signaling because of a point mutation in Unc93B1 that disrupts the 
translocation of TLRs 3,7 and 9 from the ER to endosome. The point mutation 
also affects exogenous antigen presentation through MHC class I and MHC class 
II. Severe defects are observed specifically with cross presentation. (142)  
Antibody defects observed in the 3d mice are not likely to be due to these other 
non-TLR-related defects, as similar defects are observed in MyD88-/- mice. 
Single TLR3-/-, TLR7-/-, and TLR9-/- mice did not have a defect in virus-specific 
IgG2a as MyD88-/-, 3d, TLR7/9 DKO, and IRF5-/- mice. IRF5 displays a B cell-
intrinsic role in regulating IgG2a responses and IRF5 signals downstream of 
TLR7, TLR9, and MyD88. Therefore it is likely that TLR7 and TLR9-MyD88 
pathways directly act in B cells to regulate PyV-specific IgG2a levels. 
While PyV is not known to replicate in lymphocytes (T and B cells), it is of 
interest to understand how PyV infection is sensed by endosomal TLRs in B 
cells. It is a possibility that PyV can enter B cells, but not infect them, but, so far, 
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there is no direct evidence to support this. It is not clear how endosomal innate 
receptors such as TLR7 and TLR9 are recognizing PyV directly. PyV can cause  
a lytic infection leading to the death of the infected cell. B cells are efficient at 
taking up antigen or apoptotic debris from the environment. Through this 
mechanism various antigens or TLR ligands can end up within endocytic 
pathways in B cells and interact with endosomal TLRs (121, 121, 121). Further 
studies are required to investigate this potential mechanism.  
 
C. Role of TLR pathways in long-term humoral responses to PyV  
The work in this thesis implicates MyD88-dependent TLRs in generating antiviral 
long-term B cell responses. MyD88-/-, 3d, and IRF5-/- mice generate low-levels 
of long-term PyV-specific IgG and defective numbers of long-lived plasma cells in 
the bone marrow. Experiments with individual TLR3, 7, and 9 deficient mice did 
not show the defective antibody responses seen in MyD88-/- mice. TLR7-/- mice, 
in some cases, displayed mild antibody defects. The mild defects in TLR7-/- mice 
were not always consistently significant. There are compensatory mechanisms 
that can exist in single TLR deficient mice.  
Studies with 3d mice and TLR7/9 DKO mice suggest a role for both TLR7 
and TLR9 in long-term B cell responses and in generating virus-specific IgG2a 
during a PyV infection. MCMV infection induces high levels of type I IFN and pro-
inflammatory cytokines, but the absence of both TLR9 and TLR7 abolished 
cytokine production against MCMV. The absence of only TLR7 or TLR9 did not 
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have severe defects (121). Therefore, these studies suggest that TLR7 and 
TLR9, together, are important in the IFN responses induced by the recognition of 
MCMV, a DNA virus. Similarly, both TLR7 and TLR9 play a role in antibody 
maintenance in response to PyV infection. Furthermore, it is possible that the 
paucity of VP1-specific IgG2a is affecting total IgG responses, and this may play 
a role in the observed long-term humoral defect in MyD88-/- mice.  
In addition to the role of TLRs in maintaining long-term B cell responses, 
TLR signaling has been shown to be important in vaccine studies (143). 
Immunizing mice with nanoparticles containing antigen along with ligands that 
activate both TLR4 and TLR7, synergistically, increase antigen-specific 
neutralizing antibodies (144). An understanding of TLR signaling pathways in 
mediating humoral responses is important for the generation of vaccine efficacy. 
 
D. Possible mechanisms involved in the long-term B cell defects in MyD88-
deficient mice upon PyV infection 
It is not clear if the defect in long-term B cell populations in MyD88-/- mice is 
entirely B cell-intrinsic. Our studies on TD B cell responses were done in MyD88-
/- mice, which lack MyD88 in every cell type. MyD88 signaling is important in B, T 
and antigen presenting cells such as DCs and macrophages. All of these cell 
populations play a part in generating and maintaining GC and long-term B cell 
responses.  Previously, our lab has generated data suggesting that the long-term 
antibody defect is a B cell-intrinsic issue through adoptive transfer studies. 
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Adoptively transferring MyD88-/- B cells or WT B cells into B cell deficient mice or 
transferring MyD88-/- T cells or WT T cells into T cell-deficient mice followed by 
PyV infection, we showed that mice with MyD88-/- B cells had defects in 
generating VP1-specific IgG one-month post infection. Mice with WT B cells, 
MyD88-/- T cells or WT T cells generated normal levels of virus-specific IgG (3). 
A caveat in this experiment is that within either T cell-or B cell-deficient recipient 
mice, the adoptively transferred MyD88-/- B cells or T cells were interacting with 
WT DCs and antibody responses were only observed for 30 days post infection. 
To further understand which cell type is important in maintaining long-term B cell 
responses, mixed bone marrow chimeras were generated. WT mice were 
irradiated and reconstituted at a 9:1 ratio of either TCRKO:MyD88-/- or 
µMT:MyD88-/- bone marrow cells. In WT mice reconstituted with 
TCRKO:MyD88-/- bone marrow cells the only source of T cells were from 
MyD88-/- mice, which can interact with WT B cells. On the other hand, in WT 
mice with µMT:MyD88-/- bone marrow cells the only source of B cells is from 
MyD88-/- mice, which can interact with WT T cells. Two months after the 
generation of chimeras, reconstitution of the cells was examined, followed by 
PyV infection of some mice in both groups. I used the chimeric mice in the 
adoptive transfer memory B cell assay described in this thesis. PyV-immune 
chimeric splenocytes were transferred into SCID recipients, along with control 
groups that received uninfected chimeric splenocytes. A VP1-specific ELISA was 
done at 7 days post secondary infection of SCID recipients following cell transfer. 
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SCID mice that received splenocytes from TCRKO:MyD88-/- chimeras, 
generated WT memory B cell responses. However, SCID mice with µMT:MyD88-
/- chimeric splenocytes had defective memory B cell responses, suggesting a B 
cell-intrinsic role of MyD88 in maintaining memory B cell responses to PyV 
infection. The interpretation of these experiments is difficult because the 
µMT:MyD88-/-  chimeras did not reconstitute B cells to similar numbers as seen 
in the TCR KO:MyD88-/- chimeras. This caveat can affect B cell responses 
observed in the memory B cell assay. The transfer experiments and chimeric 
mice studies, so far, suggest that T cell-intrinsic MyD88 is not essential for 
normal B cell responses and a B cell-intrinsic role of MyD88 may be important in 
maintaining long-term antibody responses. It is possible that a B cell-intrinsic 
defect can be involved in the GC and TFH cell impairments observed in MyD88-/- 
mice. As previously mentioned, interactions with B cells are required for the 
differentiation of activated CD4 T cells into TFH cells. (31, 145) B cell-intrinsic 
defects in MyD88-/- mice can affect the interaction between B cells and CD4 T 
cells, which can cause impairments in TFH cell development resulting in poor GC 
responses. 
 The absence of MyD88 signaling can affect T cell and DC activation, 
generate improper co-stimulatory signals or cytokine help to B cells (56). Studies 
with CD11c-IRF5 floxed mice show no significant differences in PyV-specific 
long-term IgG and long-lived plasma cells in the bone marrow. This suggests that 
an IRF5 defect only in DC, by itself, is not responsible for the altered long-term 
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humoral responses to PyV infection. Many other cell types, among them, FDCs, 
can influence GC and long-term B cell responses (24) (146). FDCs are important 
for antigen capture and presentation of the antigen via immune complexes to GC 
B cells for survival and selection (24). FDCs may play a role in maintaining long-
term GC responses. It is possible that, in this PyV model, the lack of MyD88 
signaling can affect the function of FDCs, which could result in defective GC 
responses and lower numbers of long-lived B cell populations. Further studies 
are necessary to determine the role of FDCs in long-term B cell responses to 
PyV infection. 
In addition to different cell types, there are various factors important for the 
maintenance and survival of long-lived plasma cells such as CXCL12, BAFF, 
APRIL, TACI, and cytokines such as IL-6 and TNF. (18) CXCL12 is a chemokine 
that attracts CXCR4+ plasmablasts to the bone marrow, the survival niche for 
long-lived plasma cells. I have examined CXCR4 expression levels on PyV-
infected MyD88-/- and WT mice 14 days post infection. No significant differences 
were observed in CXCR4 expression between the two groups. (data not shown) 
Signaling through TACI, a receptor for BAFF and APRIL, is important in the 
maintenance of long-lived antibody secreting cells, as shown in a mouse model 
of influenza infection (37). Furthermore, TACI was shown to interact with MyD88 
and trigger CSR by activating NF-kB through a TLR-like signaling pathway (147). 
I investigated antibody isotypes and long-lived PC in PyV-infected TACI deficient 
mice. The absence of TACI had no effect on VP1-specific IgG2a or IgG1 levels. 
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The isotype response to PyV infection was similar to WTB6 mice (data not 
shown) Thus, in a mouse model of PyV infection, TACI signaling did not 
influence CSR. However, TACI deficient mice had lower numbers of long-lived 
PCs in the bone marrow when compared to WTB6 mice. (data not shown) This 
suggests that TACI may be important in preserving long-lived plasma cells, and 
further studies would be required to determine whether TACI signaling through 
MyD88 or a MyD88-independent pathway affects the maintenance of long-lived 
PCs.  
 From the data presented in Chapter III, it seems that in MyD88-/- mice the 
defect in long-lived plasma cells is more severe than the defect in memory B 
cells. It may relate to the observation that long-lived plasma cells form later 
during the GC reaction than memory B cells (24), and this is consistent with the 
defects seen in the maintenance of GC in MyD88-/- mice.  All of this suggests 
that generation and maintenance of long-term B cell responses in MyD88-/- mice, 
in response to PyV infection, involves various cell types and molecules. Based 
on the data in Chapter III, it is likely that MyD88-mediated pathways are required 
in B cells for normal responses, but the MyD88-mediated pathways in other cell 
types may also contribute.  
The effects of innate signaling in the maintenance of antiviral TI humoral 
responses were examined in Chapter IV. Chapter IV shows that mice maintain 
long-lasting serological memory to PyV in the absence of T cells. This is 
achieved without the formation of GC, long-lived plasma cells in the bone marrow 
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or Bmem cells. The maintenance of this “TI serological memory”, however, 
requires high virus load and intact MyD88-mediated pathways in the host. As an 
infectious virus acting as a TI antigen, PyV differs from many well-characterized 
and frequently used TI model antigens such as bacterial polysaccharides or NP-
Ficoll.  The chemical nature of the viral capsid of PyV is protein, and not 
polysaccharide. Moreover, PyV is not inert, but a live, replicating virus, that can 
elicit innate, inflammatory or danger signals. Therefore, it was of interest to 
systematically investigate the mechanisms that allow the maintenance of 
potentially life-saving long-term IgG levels in persistently virus-infected T cell-
deficient mice. 
 
E. GC responses in T cell-deficient mice 
The formation of GC is a prerequisite for Bmem cell and long-lived BM- residing 
plasma cell formation in TD responses. GC are normally not generated in the 
absence of T cells, but under unusual circumstances, such as in BCR transgenic 
mice with a high frequency of high affinity antigen-specific B cells, or after 
immunization with TI antigens (NP Ficoll) at very high antigen doses, short lived 
GC, defined as clusters of PNA+ and GL-7+ B cells, can be induced in a T cell-
independent manner (8, 9). However, the TI GC are not functional, as no SHM 
was detected in the TI GC B cells (8), and they don’t last past day 5 following 
immunization. In this chapter, I showed that TCRβδ KO mice infected with PyV 
did not show an increase in GC B cell frequencies in the spleen on day 8-post 
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infection (the peak of the GC response) compared to the negligible levels of GC 
B cells in uninfected T cell-deficient mice. Therefore the long-lasting TI serum 
IgG responses to PyV are not products of an unusual, pathogen-induced TI GC 
reaction. 
 
F. Generation of long-lived plasma cells and memory B cells in TI B cell 
responses 
The non-secreting form of B cell memory resides in antigen-experienced 
quiescent Bmem cells, which can be rapidly activated in recall responses, giving 
faster and larger responses to re-challenge than naïve B cells which see the 
antigen for the first time. Memory B cells are usually formed in a TD response, 
but there are some reports of TI Bmem cell responses. One report by Alugupalli 
et al (6) showed that  the B1b cell population that expands during B. hermsii 
infection can survive for months in a host free of pathogen and provides long-
lasting, protective effect by secreting IgM in response to Borrelia (6, 148,). 
Immunization with the TI type 2 antigen, NP-Ficoll, also leads to B cell responses 
lasting for months. Long-lasting NP-Ficoll-specific IgM and IgG3 responses are 
generated by extrafollicular B1b plasmablasts, not by the conventional memory B 
cell populations generated from B2 cells in a usual TD antibody response. 
Another example of TI B cell memory, using the definition of antigen-
experienced, resting, non-secreting B cells for Bmem cell, Obukhanych et al. 
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reported the formation of such memory B cells, some of them isotype-switched to 
IgG, in response to the TI antigen NP-Ficoll (5).   
Studies in this chapter tested whether spleen cells of PyV-immune T cell-
deficient mice can mount a fast and enhanced recall IgG response to PyV re-
challenge in a functional adoptive transfer assay. Using this assay we found that 
recall IgG responses arose only from the splenic B cells of PyV-immune mice 
that had αβ T cells, such as wild type B6 and TCRγδ KO mice, but not from 
TCRαβKO or TCRαβγδ KO mice. Therefore, αβ T cell help is essential for the 
formation of recall Bmem cells even when immunized with PyV, an infectious 
viral TI antigen. 
 Long-lived plasma cells can maintain serological memory even in the 
absence of any other B cells, as shown by studies using CD20 depletions (149). 
The CD20-specific depleting antibodies eliminate both naïve B cells and Bmem 
cells, but spare fully differentiated plasma cells. It was determined that mice 
without T cell help, including both the CD4 T cell-defective I-Ab-/- mice (94) and 
the αβ T cell-defective TCRαβ KO or TCRαβγδ KO mice, did not accumulate 
plasma cells in their bone marrow. Therefore, long-lived plasma cells were not 
responsible for the maintenance of TI antiviral serum IgG.  
 
G. High viral loads influencing TI antibody responses 
Chapter IV demonstrates the existence of high antiviral serum IgG for as long as 
6 months after infection (the length of our study) in TCRαβ KO and TCRαβγδ KO 
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mice. While long-lasting TI IgG is observed in TCRαβγδ KO mice, our lab has 
previously published that TI IgG responses in I-Ab-/- mice were short-lived and 
greatly decreased after day 23 post infection (19, 94). How can we reconcile 
these seemingly contradictory results? A major difference between PyV-infected 
I-Ab-/- and TCRαβ KO or TCRαβγδ KO mice is the amount of persisting virus they 
harbor. Consistent with the antiviral role of CD8 T cells, I-Ab-/- mice have CD8 
cytotoxic T cell responses and a low level of PyV persistence, undistinguishable 
from that of wild type B6 mice. On the other hand, TCRαβ KO or TCRαβγδ KO 
mice lack CD8 T cell responses and have about ten-fold higher persisting PyV 
load compared to B6 mice. We propose that the high virus load continuously 
activates naïve B cells, maintaining the serum antibody levels by IgG secretion 
by short-lived PC. In the CD4 T cell-deficient I-Ab-/- mice the virus load may not 
be sufficiently high to assure continuous B cell activation and sustained IgG 
responses. This scenario is supported by our data showing that transfer of CD8 T 
cells into T cell-deficient mice decreases virus load and is also associated with a 
reduction of antiviral IgG responses with time, similarly to what was seen in I-Ab-/- 
mice.  
 
H. Role of innate pathways in maintaining TI antibody responses 
The high virus load in TCRαβ KO or TCRαβγδ KO mice is not restricted to the 
periphery; it is also present in the bone marrow, where B cells continuously 
develop. This brings up the question of how can B cells that develop and 
166
differentiate in the presence of PyV antigens maintain their reactivity and not 
become tolerized to PyV?  Most viral infections activate innate immune 
responses and induce multiple inflammatory signals, which serve as the first line 
of defense against an infection. These innate responses may be important for the 
early control of pathogens, but they also shape the adaptive immune responses. 
We have found previously that PyV infection activates MyD88-mediated 
pathways, and these pathways play a crucial role in the maintenance of long-
term IgG responses to PyV infection in immunocompetent (T cell sufficient) mice 
(3). MyD88 mediates signaling from most TLRs (except TLR3) and the cytokine 
receptors IL-1R and IL-18R. For the induction of long-lasting IgG responses to 
PyV the cytokine receptors were dispensable (3). These experiments show that 
PyV can be considered as a “dual specificity” antigen, which can simultaneously 
engage B cell receptors and TLRs. Remarkably, in transgenic B cell models the 
presence of an antigen with this “dual specificity” was shown to lead to a breach 
of anergy (128). Self-antigens that could bind the B cell receptor and engage 
TLR7 or TLR9 generated autoantibodies (20, 150).  PyV, which is present in the 
bone marrow, can engage the BCR, become endocytosed and potentially be 
recognized by endosomal TLR7 or TLR9-MyD88 mediated pathways. This 
recognition of PyV by both the BCR and the endosomal TLRs could be a key 
step in allowing continuous PyV-specific antibody production. While investigating 
the role of innate MyD88-mediated pathways in the maintenance of long-term 
IgG in T cell-deficient mice, we found that the lack of sustained IgG responses in 
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mice deficient in both T cells and MyD88 signaling contrasted with long lasting TI 
serum IgG in MyD88 sufficient T cell-deficient mice. This suggests that the 
continuous activation of naïve B cells emerging from the bone marrow by the 
high virus load is successful only if the antigen also activates the innate immune 
pathways. MyD88 signaling, as shown in Chapter III, is important in antibody 
isotype responses and in the maintenance of long-lasting antibody responses in 
T cell-sufficient mice.. Thus, a possible alternative scenario is that the defect in TI 
IgG responses in TCR?? KO/MyD88-/- is due to a requirement for MyD88 in TI 
switching to IgG. However, our data showing similar low levels of IgM in both 
TCRbdKO and TCRbdKO/MyD88-/- mice argue against this possibility. Our study 
shows that although short-lived TI antibody secretion does not require MyD88-
mediated pathways in virus-infected T cell-deficient mice, the long-term 
maintenance of the antiviral serum antibody levels, which is often life-saving, in 
the absence of T cells, requires the activation of innate pathways.  
In summary, studies described in Chapter IV are consistent with the 
hypothesis  that innate immune activation and high antigen load, together, can 
break tolerance of developing B cells. This proposed tolerance breaking 
mechanism  may act as a safeguard to assure protective humoral immunity 
against a viral pathogen even under the conditions of partial immunodeficiency 
(lack of T cells). Furthermore, this mechanism would greatly reduce the long-term 
production of irrelevant or auto-reactive antibodies and the occurrence of 
pathogenic autoantibody-induced conditions.  
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I. Conclusions 
The PyV mouse model has allowed me to ask how innate signaling 
contributes to the maintenance of life-long antiviral antibodies in 
immunocompetent hosts and T cell-deficient mice infected with this persistent 
virus. 
We have reported previously that long-term humoral immunity to PyV was 
defective in mice that lacked MyD88, as the MyD88-/- mice failed to form long-
lived plasma cells (3). The results in Chapter IV taken together with the previous 
findings suggest that there are important mechanisms that assure that long-lived 
antibody responses, both TI and TD, are maintained only to those antigens that 
turn on innate immunity by their pathogen-associated molecular patterns, which 
can represent “danger” to the host. 
Results from Chapter III show the importance of MyD88-mediated TLR 
pathways in regulating isotype-switched, long-term B cell responses to PyV 
infection. In spite of that, I have shown that MyD88 signaling is important in 
maintaining TFH cell and GC B cell numbers, assuring the relative longevity of 
GC reaction, which contributes to the normal generation of long-term B cell 
responses. Studies in Chapter IV demonstrate how the presence of antigen at 
high levels and innate signaling pathways preserve TI antibody responses. The 
key aspect in these studies was the amount of antigen present within the bone 
marrow. An antigen that could reach a threshold that could trigger both BCR and 
TLR pathways leading to the break in B cell tolerance. Thus, this mechanism is 
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of biological importance as it can provide long-term humoral protection against 
foreign pathogens, such as virus infections that are uncontrolled and grow in 
immune compromised mice. 
 TD and TI B cell responses were studied here in a PyV mouse model, but 
our findings on the role of MyD88-mediated TLR signaling pathways in promoting 
both TD and TI long-term B cell responses are likely to apply to other viral 
infections as well (116, 151). 
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